Entries |
Document | Title | Date |
20080213211 | COMPOSITIONS AND METHODS FOR HEALTHY PREGNANCY - Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of an embryo. | 09-04-2008 |
20080219946 | THERAPEUTIC AGENT AND METHOD FOR OVULATION DISORDER CAUSED BY LUTEINIZED UNRUPTURED FOLLICLE - A therapeutic agent for ovulation disorder of the present invention is characterized in comprising Granulocyte colony-stimulating factor; and that the ovulation disorder is caused by Luteinized Unruptured Follicle. | 09-11-2008 |
20080226587 | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION - Compositions for immunomodulation that include acylated peptide antigens recognized by CD1c-restricted T cells, and methods of using the compositions, are provided herein. | 09-18-2008 |
20080260684 | Method for the Purification of G-Csf - The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively. | 10-23-2008 |
20080260685 | PRODRUGS OF CC-1065 ANALOGS - Prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group such as a piperazino carbamate, a 4-piperidino-piperidino carbamate or a phosphate, in which the protecting group confers enhanced water solubility and stability upon the prodrug, and in which the prodrug also has a moiety, such as a disulfide, that can conjugate to a cell binding reagent such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have therapeutic use because they can deliver cytotoxic prodrugs to a specific cell population for enzymatic conversion to cytotoxic drugs in a targeted fashion. | 10-23-2008 |
20080299071 | Stable aqueous solutions of granulocyte macrophage colony-stimulating factor - The invention provides formulations of GM-CSF to which a chelating agent has been provided to stabilize the GM-CSF against N-terminal degradation. | 12-04-2008 |
20080299072 | Chemokine Antagonists - New CC-chemokine antagonists are provided. Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immunomodulatory compounds and in the treatment or prevention of CC-chemokine-related diseases. | 12-04-2008 |
20080317705 | Promoting Wound Healing by Administering a Prostaglandin E and Granulocyte-Macrophage Colony Stimulating Factor - A method of promoting healing of a wound in a patient, the method comprising administering to the patient (i) a prostaglandin E (PGE) or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) granulocyte-macrophage colony stimulating factor (GMCSF) or a derivative thereof. Use of (i) a PGE or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) GMCSF or a derivative thereof in the preparation of a medicament for promoting healing of a wound in a patient. A wound dressing, bandage or fibrin glue comprising (i) a PGE or an agonist thereof and/or an agent that increases the local concentration or effect of PGE and (ii) GMCSF or a derivative thereof. | 12-25-2008 |
20090004134 | KIT FOR TREATING A HEALTH CONDITION BY INDUCING TRANSLOCATION OF AN ERP57 PROTEIN TO A CELLULAR MEMBRANE - A kit for treating a health condition in a mammal, comprises a ERP57 protein and/or compound for inducing a translocation of an ERP57 protein to a cellular membrane in order to provoke an immunogenic apoptosis. The ERP57 protein may include any one or more of: endogenous ERP57, recombinant ERP57, and ERP57 in mimetic form. The endogenous form of ERP57 may include any one of: a plasma membrane ERP57 and an intracellular ERP57. | 01-01-2009 |
20090028814 | HIGH MOLECULAR WEIGHT MEDICINE-CONTAINING PREPARATION IN POWDER FORM FOR ADMINISTRATION THROUGH MUCOSA - A preparation in powder form for administration through mucosa, comprising a medicine of high molecular weight and a cationic polymer is disclosed. | 01-29-2009 |
20090068139 | LOOP PEPTIDE AND TGF alpha FOR STIMULATING STEM CELL PROLIFERATION AND MIGRATION - There is disclosed a novel genus of small peptides, smaller than human TGFα, identified as having TGFα biological activity and therefore being useful as pharmacologic agents. It is further disclosed that both TGFα and the genus of small peptides disclosed herein have therapeutic activity to stimulate hematopoiesis, e.g., in patients undergoing cytotoxic cancer chemotherapy, and also act as cytoprotective agents to protect patients undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis, and otherwise to support the barrier function of the GI tract, such as when it is harmed by cytotoxic therapy. | 03-12-2009 |
20090081155 | Use of Inhibitors of Indoleamine-2,3-Dioxygenase in Combination with Other Therapeutic Modalities - The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent. | 03-26-2009 |
20090087403 | REVERSAL OF VIRAL-INDUCED SYSTEMIC SHOCK AND RESPIRATORY DISTRESS BY BLOCKADE OF THE LYMPHOTOXIN BETA PATHWAY - This invention provides methods of inducing an antiviral response in an individual comprising administering to the individual an effective amount of a LT-B blocking agent and a pharmaceutically acceptable carrier. In particular this invention provides methods for treating viral-induced systemic shock and respiratory distress. | 04-02-2009 |
20090110659 | Human chemotactic cytokine - The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections. | 04-30-2009 |
20090130054 | APC ACTIVATORS IN COMBINATION WITH A CYTOKINE-SECRETING CELL AND METHODS OF USE THEREOF - The present invention relates to a method of enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising antigen presenting cell (APC) activators and a cytokine-secreting cell and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer. | 05-21-2009 |
20090148400 | COMPOSITION OF TUMOUR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumour immune responses against colorectal cancer. | 06-11-2009 |
20090191146 | METHODS FOR THE MODULATION OF NEOVASCULARIZATION AND/OR THE GROWTH OF COLLATERAL ARTERIES AND/OR OTHER ARTERIES FROM PREEXISTING ARTERIOLAR CONNECTIONS - Described is the modulation of the neovascularization and/or growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting organs, tissue or cells with a colony stimulating factor (CSF) or a nucleic acid molecule encoding said CSF. Furthermore, the use of a CSF or a nucleic acid molecule encoding said CSF for the preparation of pharmaceutical compositions for enhancing neovascularization and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections is described. Also provided are methods for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of CSFs. Described is further the use of an agent which suppresses neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through inhibition of the biological activity of CSFs for the preparation of pharmaceutical compositions for the treatment of tumors. | 07-30-2009 |
20090202469 | Detection of inflammatory disease and composition for preventing or treatment of inflammatory disease - A novel method for detection of an inflammatory disease and a novel composition for prevention or treatment of an inflammatory disease are provided. The method for detection of an inflammatory disease comprises using RANKL and/or OPG as a marker in a biological sample. The composition for prevention or treatment of an inflammatory disease comprises RANKL and/or M-CSF as an active ingredient. | 08-13-2009 |
20090208446 | DUB3 as a Cancer Therapy Target - Described is a method of modulating the activation of a Rho, Arf, Rab, Ran or Rap family protein, said method comprising administering to said sample a USP-17 modulator, for example an inhibitor of expression or activity of DUB-3. The invention enables the use of USP-17 modulators in the treatment of metastatic cancer and other conditions. | 08-20-2009 |
20090238788 | DELIVERY OF HYDROGELS AS SPRAYS - A method for delivering β-sheet peptide hydrogels to a target surface by shear-thinning and spraying the peptide hydrogel on the surface is provided. The β-sheet peptide hydrogels can be applied over a range of thicknesses and can cover broad surface areas. The β-sheet peptide hydrogels may also include a therapeutic agent. | 09-24-2009 |
20090263348 | Nucleic Acids Encoding Multimeric Fusion Proteins of TNF Superfamily Ligands - A method for constructing stable bioactive fusion proteins of the difficult to express turn or necrosis factor superfamily (TNFSF), and particularly members CD40L (CD 154) and RANKL/TRANCE, with collecting, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these soluble fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be especially useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addition, these and other TNFSF-collectin fusion proteins present new possibilities for the expression of highly active, multimeric, soluble TNFSF members. | 10-22-2009 |
20090297470 | REMEDIES FOR ISCHEMIA - The present invention relates to uses and methods of parathyroid hormone (PTH), preferably PTH (1-34), and/or parathyroid hormone-related peptide (PTHrP), preferably PTHrP (1-34), for recruiting stem cells into tissue suffering from ischemia, wherein said stem cells are preferably capable of repairing and/or regenerating said tissue suffering from ischemia. Also provided is the use of a combination of G-CSF or a G-CSF fragment and a DPP IV inhibitor/antagonist in the medical intervention of an ischemic disorder. Accordingly, the uses and methods of the present invention are preferably suitable for the prevention and/or treatment of ischemia. Moreover, the present invention relates to a composition comprising parathyroid hormone (PTH), preferably PTH (1-34), and/or parathyroid hormone-related peptide (PTHrP), preferably PTHrP (1-34), and/or G-CSF or a G-CSF fragment for use as a pharmaceutical composition. In a particular aspect of the invention, a DPP IV antagonist is applied in the uses, methods and/or compositions of the present invention. The DPP IV antagonist/inhibitor is preferably used in combination with G-CSF or a G-CSF fragment. Also the use of PTH alone or PTHrP alone or in combination with a DPP IV antagonist as well as the one of a combination of G-CSF or a G-CSF fragment and a DPP IV inhibitor/antagonist in the herein disclosed medical and pharmaceutical uses and methods is part of this invention. | 12-03-2009 |
20100015085 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION/INFECTION, APOPTOSIS AND STRESS - Disclosed herein are novel compounds, their use in the treatment and prevention of joint and/or cartilage inflammation that provide an alternative to the NSAIDS and selective COX-2 inhibitors by activating endogenous detoxifying cellular defense mechanisms that act to neutralize toxic cellular intermediate. These compounds are PPAR-alpha agonists and/or phase 2 gene activators. | 01-21-2010 |
20100021419 | Stable Pharmaceutical Composition Comprising Granulocyte-Colony Stimulating Factor - The present invention provides a new stable pharmaceutical composition of granulocyte-colony stimulating factor (G-CSF). | 01-28-2010 |
20100080769 | Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies - Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen. | 04-01-2010 |
20100092423 | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CD6 MONOCLONAL ANTIBODY USED IN THE DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS - The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis. | 04-15-2010 |
20100129313 | KIDNEY-SPECIFIC TUMOR VACCINE DIRECTED AGAINST KIDNEY TUMOR ANTIGEN G-250 - This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy. | 05-27-2010 |
20100129314 | POTENT CONJUGATES AND HYDROPHILIC LINKERS - Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided. | 05-27-2010 |
20100135951 | Agents and Methods Related to Reducing Resistance To Apoptosis-Inducing Death Receptor Agonists - Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins. | 06-03-2010 |
20100143288 | HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR ISOFORMS - Disclosed is a novel physiologically active protein, which is a human granulocyte colony stimulating factor isoform, constructed in order to increase the in vivo lifetime of human granulocyte colony sedtimulating factor. The human granulocyte colony stimulating factor isoform comprises a polypeptide and polyethylene glycol (PEG) bound thereto as a non-protein polymer. A specific site of the polypeptide is selected so that polyethylene can be bound to the site while not adversely affecting the activity of the protein. The amino acid of the site is modified with cysteine and polyethylene glycol is bound to the modified site. A pharmaceutical composition comprising the isoforms, genes encoding the isoforms, and a primer for modifying the amino acid sequence are also disclosed. | 06-10-2010 |
20100143289 | UMBILICAL CORD STEM CELL SECRETED PRODUCT DERIVED TOPICAL COMPOSITIONS AND METHODS OF USE THEREOF - Compositions including topical formulations comprising secreted products obtained from the culture medium of human umbilical cord stem cells and particular combinations of components therefrom are provided for treatment of various dermatological conditions, such as adverse consequences of aging, wrinkling, altered pigmentation, altered viscoelasticity, and altered thickness, among others. Methods for using the compositions and topical formulations for treating adverse or undesirable dermatological conditions are also provided, as well as preventing the appearance of undesirable dermatological conditions. | 06-10-2010 |
20100143290 | MONOCLONAL ANTIBODIES TO HUMAN THYMIDINE KINASE TO TREAT CANCER - A method of treatment of cancer, viral infections, and the like administers anti-TK1 antibody, constituted as the complete antibody or a fragment thereof. The antibody binds to the surface of cells expressing TK1 thereon. The antibody, with or without another agent bound thereto, may effect complement mediated lysis, antibody-dependent cell-mediated cell cytotoxicity, apoptosis, an immune response by the mammal, a reduction in cellular replication, a combination thereof, or the like for such cells. The antibody may be coupled to an immune response stimulator, a cytotoxin, an enzyme, a combination, or the like to effect the treatment desired. | 06-10-2010 |
20100150860 | RECOMBINANT CHIMERIC PROTEIN OF NEUTROPHIL INHIBITORY FACTOR AND HIRUGEN, AND PHARMACEUTICAL COMPOSITION THEREOF - Provided is a chimeric protein comprising neutrophil inhibitory factor, the peptide FRRP specially recognizing the thrombin active site and hirugen. Also provided is a pharmaceutical composition comprising the chimeric protein, which can be used for treating or preventing cerebral injury and cerebral edema, inhibiting platelet aggregation etc. | 06-17-2010 |
20100158856 | Assays and methods using biomarkers - Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided. | 06-24-2010 |
20100166697 | COMBINATION THERAPY USING TNF AND ALFA-GALACTOSYL CERAMIDE - The invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of TNF and alfa-galactosylceramide. | 07-01-2010 |
20100166698 | NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION - The present invention describes combinations of A | 07-01-2010 |
20100178271 | Combination Therapy - Methods to mobilize progenitor and/or stem cells from the bone marrow to the bloodstream by administering a combination of at least one CXCR | 07-15-2010 |
20100196308 | VITAMIN D3 AND ANALOGS THEREOF FOR ALLEVIATING SIDE EFFECTS ASSOCIATED WITH CHEMOTHERAPY - The present disclosure relates to the use of vitamin D compounds, such as vitamin D3, or analogs and/or metabolites thereof, to modulate bone marrow progenitors and stromal cells prior to the administration of antineoplastic agents. The methods of the present disclosure may ameliorate myelosuppression by increasing the availability of pluripotent stem cell progenitors, and can be used in combination with standard therapy (e.g. granulocyte stimulating factor) to increase proliferation of myeloid cells and/or improve their mobilization from the bone marrow, thereby diminishing the dose and administration of colony-stimulating factors (CSFs) as well as the recuperation time following chemotherapy. | 08-05-2010 |
20100203007 | NOVEL BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 08-12-2010 |
20100209383 | Use of g-csf for treating ischemia - The present invention relates to uses of granulocyte colony stimulating factor (GCSF) or fragment thereof for the preparation of a pharmaceutical composition for treating organ dysfunction caused by ischemia, whereby the pharmaceutical composition is to be administered to a patient who is subjected to a surgical or interventional procedure in order to improve organ function, to improve organ function, to improve blood flow and/or to induce revascularization. Furthermore, the present invention relates to methods of treating organ dysfunction caused by ischemia comprising administering a therapeutically effective amount of G-CSF or fragment thereof to a patient who is subjected to a surgical or interventional procedure in order to improve organ function, to improve organ function, to improve blood flow and/or to induce revascularization. | 08-19-2010 |
20100247481 | ABCB1 GENOTYPING TO PREDICT MICROTUBULE-STABILIZING-AGENT-INDUCED TOXICITY - The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G>T/A and 3435C>T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided. | 09-30-2010 |
20100254937 | METHODS OF USING INTERLEUKIN-1 RECEPTOR ANTAGONIST AS A MYELOPROTECTIVE AGENT - The present invention relates to uses of interleukin-1 receptor antagonist (IL-1Ra) in promoting bone marrow regeneration, increasing peripheral white blood cells, and increasing platelet levels in subjects if administered prior to treatment with chemotherapeutic agents. Thus, particular embodiments of the invention are directed to uses of IL-1Ra as an adjuvant or ancillary therapy to alleviate the hematopoietic toxicities associated with chemotherapy. | 10-07-2010 |
20100254938 | FORMULATION HAVING MOBILISING ACTIVITY - The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterised in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilise haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone. | 10-07-2010 |
20100266528 | Systemic Administration of Colony Stimulating Factors to Treat Amyloid Associated Disorders - The invention relates a method of treating amyloidosis, diseases and disorders associated with amyloid plaque formation, e.g., Alzheimer's disease by increasing tissue resident macrophage activity in an organ or tissue of an animal requiring treatment by systemic administration of a colony stimulating factor. For example, the activity of bone marrow-derived microglial cells in an organ or tissue can be increased by systemic administration of a colony stimulating factor, particularly macrophage colony stimulating factor, either alone or in combination with additional colony stimulating factors, stem cell factors or other compounds capable of treating amyloidosis. | 10-21-2010 |
20100266529 | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof - The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention. | 10-21-2010 |
20100284961 | MCP-1 binding nucleic acids - The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ. ID. No. 87 to 115. | 11-11-2010 |
20100284962 | MODIFIED TUMOR NECROSIS FACTOR-BETA - Compositions including modified TNF-beta polypeptides and methods of using the compositions are disclosed herein. | 11-11-2010 |
20100297060 | ENHANCEMENT OF ANTIBODY-CYTOKINE FUSION PROTEIN MEDIATED IMMUNE RESPONSES BY COMBINED TREATMENT WITH IMMUNOCYTOKINE UPTAKE ENHANCING AGENTS - Disclosed are methods and compositions for treating tumors. Disclosed methods and compositions enhance the uptake of immunocytokines into tumors, and are based on a combination of an immunocytokine with an immunocytokine uptake enhancing agent. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal. | 11-25-2010 |
20100297061 | STAT3 ANTAGONISTS AND THEIR USES AS VACCINES AGAINST CANCER - The present invention relates to methods for treating and/or preventing cancer. In particular the present invention relates to ex vivo immunotherapeutic methods. The methods comprise decreasing Stat3 (signal transducer and activator of transcirption3) expression and/or function in tumor cells and the administration of such cells to a subject in need of treatment and/or prevention. Other methods of the invention comprise activation T-cells by co-culturing the T-cells with the tumor cells with decreased Stat3 expression or function. The invention further encompasses methods comprising decreasing Stat3 expression or function in antigen-presenting cells and co-administering tumor cells and the antigen-presenting cells with decreased Stat3 function to a patient. The invention further relates to methods for stimulating dendritic cell differentiation. | 11-25-2010 |
20100297062 | Stable Formulations Of Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor - Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described. | 11-25-2010 |
20100310500 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS - The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 12-09-2010 |
20100316592 | AQUEOUS PREPARATION COMPRISING eMIP AS ACTIVE INGREDIENT - An objective of the present invention is to provide aqueous preparations comprising eMIP, a derivative of macrophage inflammatory protein 1α (MIP-1α) which has an immunopotentiation activity, and stabilizer(s). The present inventors conducted dedicated studies to achieve the above-described objective. As a result, the present inventors discovered that eMIP degradation is suppressed by addition of at least one or more additives selected from sodium chloride, L-histidine, L-arginine, L-arginine hydrochloride, L-lysine hydrochloride, citric acid, and sodium edetate (EDTA). Furthermore, the present inventors demonstrated that phosphate buffer of pH 5 to pH 7 is a preferable pH adjuster for the aqueous eMIP preparations of the present invention. | 12-16-2010 |
20100316593 | Pharmaceutical Formulations - A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte. | 12-16-2010 |
20100322893 | CTLA-4 PROTEIN VARIANTS - Protein variants of CTLA-4, which show increased activity compared to wild-type in a cell assay and which exhibit increased stability. Such variants are useful for treatment of disorders whereby attenuation of the T cell response would be beneficial. | 12-23-2010 |
20100322894 | Combination Therapies for Treating Type 1 Diabetes - In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes. | 12-23-2010 |
20110002879 | Combinations of Pyrazole Kinase Inhibitors - The invention provides a combination comprising a cytotoxic compound, a signalling inhibitor, an ancillary agent, or two or more further anti-cancer agents, and a compound having the formula (Ib): | 01-06-2011 |
20110008278 | MODULATORS OF PARAPTOSIS AND RELATED METHODS - The invention is directed to a method of modulating paraptotic cell death in a cell by contacting the cell with an effective amount of a compound. selected from the group consisting of ceramide, Tumor Necrosis Factor (TNF), caspase-7, caspase-8, α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (RMPA), kainic acid and glutamic acid, wherein the effective amount of the compound induces paraptotic death of the cell. The invention further is directed to a method of inhibiting paraptotic cell death in a cell by contacting the cell with an effective amount of a compound selected from the group consisting of Alg-2-interacting protein 1 (AIP-1), Jun N-terminal kinase 1 (JNK1) neutralizing agent, Jun N-terminal kinase 2 (JNK2) neutralizing agent, TNF Receptor-Associated Factor 2 (TRAF2) neutralizing agent, ortho-phenanthroline and the JNK inhibitor SP 600125, wherein the effective amount of the compound inhibits paraptotic death of the cell. | 01-13-2011 |
20110014152 | INCREASED T-CELL TUMOR INFILTRATION AND ERADICATION OF METASTASES BY MUTANT LIGHT - Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed. | 01-20-2011 |
20110014153 | REINFORCED TISSUE GRAFT - A biocompatible tissue graft is provided. The tissue graft includes an extracellular matrix patch and a means for reinforcing the patch. | 01-20-2011 |
20110020266 | G-CSF Conjugates - Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF. | 01-27-2011 |
20110020267 | TWEAK RECEPTOR - The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue. | 01-27-2011 |
20110020268 | AGENT COMPRISING G-CSF FOR TREATMENT OF TRAUMATIC PERIPHERAL NERVE INJURY AND METHOD FOR TREATING TRAUMATIC PERIPHERAL NERVE INJURY WITH THE SAME - Disclosed herein are an agent for treating traumatic peripheral nerve injury comprising a granulocyte colony stimulating factor (G-CSF) as an active ingredient and a method for treating traumatic peripheral nerve injury with the same. | 01-27-2011 |
20110027218 | TNF SUPERFAMILY FUSION PROTEINS - The present invention refers to fusion proteins comprising a TNF superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a trimerization domain and a nucleic acid molecule encoding the fusion protein. The fusion protein is present as a trimeric complex or as an oligomer thereof and is suitable for therapeutic, diagnostic and/or research applications. | 02-03-2011 |
20110027219 | Treatment of Crohn's disease with laquinimod - This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease. | 02-03-2011 |
20110033414 | CARDIOVASCULAR THERAPY COMPOSITION INCLUDING TRANSFER FACTOR AND THERAPEUTIC METHODS INCLUDING USE OF THE COMPOSITION - A composition for use in cardiovascular therapy includes transfer factor. The transfer factor may be nonmammalian transfer factor, such as that derived from eggs, or mammalian transfer factor, such as that derived from colostrum. The composition may also include one or more of the following: an LDL receptor-binding element; a blood flow-enhancing element; a cholesterol reducing element; a fat oxidation prevention element, and an antioxidant. Treatment methods include enlisting the immune system of a subject receiving therapy to attack pathogens that cause inflammation of blood vessels or to otherwise reduce inflammation of blood vessels. | 02-10-2011 |
20110038830 | COSMETIC USE OF PLAKOGLOBIN-TYPE PROTEINS - The present invention relates to the use, in particular cosmetic and/or therapeutic use, of plakoglobin, of polypeptides derived from this protein or of analogs thereof, of a nucleic sequence encoding such a polypeptide or of an agent for modulating the activity, the stability or the expression of such a polypeptide, in particular for stimulating terminal epithelial differentiation. The invention also relates to the use of plakoglobin, of polypeptides derived from this protein or of analogs thereof, or of a nucleic sequence encoding such a polypeptide, as a marker for evaluating a state of an epithelium. | 02-17-2011 |
20110038831 | COMBINED USE OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS TO INCREASE RED BLOOD CELL LEVELS - In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. | 02-17-2011 |
20110052525 | Breaking Immunological Tolerance with a Genetically Encoded Unnatural Amino Acid - The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against a version of a target moiety having one or more unnatural amino acid which antibody is cross reactive with the natural target moiety. | 03-03-2011 |
20110052526 | METHOD AND COMPOSITION FOR NEOCHONDROGENESIS - A method of neochondrogenesis, where following microfracture surgery or subchondral drilling, includes administering injections of an effective amount of a composition to the damaged, affected connective tissue, for example knee joint cartilage. The composition includes a mixture of hyaluronic acid combined with harvested stem cells, for example autologous peripheral blood-derived stem cells. | 03-03-2011 |
20110052527 | IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS - A compound of general Formula (I) having histone deacetylase (HDAC) and/or CDK inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 03-03-2011 |
20110070184 | METHODS AND COMPOSITIONS FOR TREATING ATHEROSCLEROSIS AND RELATED CONDIDTIONS - Described herein are methods for treating or preventing a atherosclerosis by inhibiting the activation or binding of macrophage migration inhibitory factor to CXCR2 and CXCR4. Such inhibition is achieved by administration of either a single agent or a combination of agents. Also described herein are agents that inhibit MIF-binding or MIF-activation of CXCR2 or CXCR4. Further described are pharmaceutical compositions comprising such agents and their use for treating or preventing atherosclerosis. | 03-24-2011 |
20110076247 | AGENT COMPRISING G-CSF FOR PREVENTION AND TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY - Disclosed is an agent for preventing and treating diabetic peripheral neuropathy including a granulocyte colony stimulating factor (G-CSF) as an active ingredient, which is able to improve nerve conduction velocity and pain sensitivity by regenerating blood vessels in peripheral tissues and rehabilitating damaged nerve tissues. | 03-31-2011 |
20110091410 | Engineered CXCL12 Alpha Locked Dimer Polypeptide - The present invention provides a novel CXCL12-α | 04-21-2011 |
20110097300 | MULTIMERIC TIE 2 AGONISTS AND USES THEREOF IN STIMULATING ANGIOGENESIS - The present invention provides a multimeric form of a Tie 2 binding peptide monomer, wherein the multimeric form has Tie 2 agonist activity. The multimeric form, preferably a tetramer, stimulates angiogenesis and promotes wound healing. The present invention also features pharmaceutical compositions comprising the multimeric Tie 2 agonists, including those suitable for topical or systemic administration. Methods of using the multimeric Tie 2 agonists of the invention for stimulating angiogenesis and for promoting healing of wounds, such as diabetic ulcers or skin grafts, are also provided. | 04-28-2011 |
20110097301 | ANGIOGENESIS PROMOTED BY CAGED GROWTH FACTORS - The present disclosure relates to controlling the release of growth factors for the promotion of angiogenesis. The growth factors or a polymer matrix are modified by photoactive compounds, such that the growth factors are not released into an active form until they are irradiated with light. The disclosure also relates to tissue engineering scaffolds comprising one or more polymers and at least two growth factors. | 04-28-2011 |
20110104100 | COMPOSITIONS AND METHODS OF STEM CELL THERAPY FOR AUTISM - Disclosed are methods, compositions of matter, and cells, useful for the treatment of autism, social integrative disorders, and various cognitive abnormalities. The invention discloses, inter alia, means of substantially ameliorating or reversing the progression of autism through the administration of autologous and/or allogeneic stem cells, alone or in combination with mobilization agents. The use of stem cells and cells naturally possessing or endowed with angiogenic and anti-inflammatory activity are disclosed for autism either alone or in combination with various therapeutic interventions. | 05-05-2011 |
20110104101 | Immunotherapy for Unresectable Pancreatic Cancer - The present invention provides a novel cancer immunotherapy comprising a vaccination schedule of both intratumoral and systemic injections followed by peripheral boost injection. The immunotherapy can then be followed by other standard treatment as is known in the art for locoregional or metastatic pancreatic cancer. The present invention further provides a kit for administering the cancer immunotherapy described herein. The present invention further provides a method of decreasing the dose of cancer immunotherapy vaccines. | 05-05-2011 |
20110104102 | METHOD FOR STIMULATING MAMMALIAN CELLS AND MAMMALIAN CELL - The current invention relates to methods for stimulating mammalian cells to enhance their ability to cross the blood-brain-barrier and to phagocytose and degrade beta-amyloid plaques in the brain. The current invention also relates to cells obtained by the method of the invention. The current invention also relates to methods for prevention and treatment of amyloid-accumulating disorders. | 05-05-2011 |
20110110883 | METHODS OF ALTERING AN IMMUNE RESPONSE INDUCED BY CPG OLIGODEOXYNUCLEOTIDES - It is disclosed herein that agents that affect the activity and/or expression of CXCL16 can be used to alter the uptake of D-type CpG oligodeoxynucleotides (D ODNs). Methods of inducing an immune response are disclosed that include administering agents that increase the activity and/or expression of CXCL16 and a D ODN. Methods of decreasing an immune response to a CpG ODN are also disclosed. These methods include administering an agent that decreases the activity and/or expression of CXCL16. Compositions including one or more D-type ODNs and an agent that modulates that activity and/or expression of CXCL16 are provided. | 05-12-2011 |
20110117049 | Methods and Compositions for Modulating Adipocyte Function - Methods and compositions for treating obesity and related disorders. The methods include the use of BMP-2, -4, -6 and -7. | 05-19-2011 |
20110117050 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen - The present invention provides methods of treating subjects with an oxazaphosphorines, methods of identifying subjects that are suitable for oxazaphosphorine treatment, and systems for ensuring the safety and efficacy of a treatment that includes oxazaphosphorine administration. | 05-19-2011 |
20110123480 | CHIMERIC PROTEINS AND USES THEREOF - The present invention provides a chimeric protein capable of killing or modifying a cell expressing abnormally high levels of a ligand of a receptor of the TNF/NGF family, comprising the amino acid sequence of at least one polypeptide consisting of an extracellular portion of said receptor connected to an effector molecule. In addition the invention provides pharmaceutical compositions comprising said chimeric protein and use thereof. | 05-26-2011 |
20110123481 | ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR THERAPEUTIC AND COSMETIC APPLICATIONS - A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm | 05-26-2011 |
20110123482 | Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide - Described herein are methods for treating neurological autoimmune disorders in which the treatment method includes administering an immunoablative agent to eliminate most or essentially all maturing and mature elements of the immune system in an affected individual. Following this step, the individual is administered agents to reestablish the ablated immune system. | 05-26-2011 |
20110123483 | HMGB1 FOR CANCER TREATMENT - The current invention relates to a method for treating a subject suffering from cancer comprising administering to said subject a therapeutically effective dose of High Mobility Group B1 (HMGB1) protein or of a polynucleotide comprising a coding region for an HMGB1 gene in an expressible form. Moreover, it relates to the combination of said method with other cancer treatment regimens. | 05-26-2011 |
20110129438 | IMMUNOGENIC PROTEIN CONSTRUCTS - Bacterial immunity proteins are utilized to increase immune response to an antigen of interest. | 06-02-2011 |
20110135594 | OXINDOLYL INHIBITOR COMPOUNDS - A compound of general Formula (I) having histone deacetylase (HDAC) and/or CDK inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. (Formula should be inserted here) Formula (I) | 06-09-2011 |
20110142791 | COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS - This invention provides compositions and methods for treating and vaccinating against an Her2/neu antigen-expressing tumor and inducing an immune response against dominant and several sub-dominant epitopes of the antigen. | 06-16-2011 |
20110142792 | Compositions for Increasing Polypeptide Stability and Activity, and Related Methods - This disclosure provides peptides, polypeptides, fusion polypeptides, compositions, and methods for enhancing or increasing the stability of a polypeptide (e.g., Taq polymerase). Such peptides, polypeptides, fusion polypeptides, or compositions include polypeptides linked to a peptide tag that enhances the stability of the polypeptide. The peptides, polypeptides, fusion polypeptides, compositions may also enhance the activity, specificity, and/or fidelity of other polypeptides in a reaction mixture. The disclosure also provides methods of using such peptides, polypeptides, fusion polypeptides, compositions. | 06-16-2011 |
20110150823 | Cell Tissue Gel Containing Collagen and Hyaluronan - A cell tissue gel containing collagen and hyaluronan at a weight ratio of 0.01-100:1 and uses thereof for stem cell delivery. | 06-23-2011 |
20110150824 | Nutritional Composition for Improving the Mammalian Immune System - The invention relates to a nutritional composition comprising
| 06-23-2011 |
20110158935 | Substituted Diketopiperazine Analogs for Use as Drug Delivery Agents - Disclosed are drug delivery systems for the delivery of small molecule and macromolecular drugs. More particularly, disclosed are substituted analogs of 3,6-di(alkyl-4 aminobutyl)-2,5-diketopiperazine (which may also be referred to DKP), their use in the formulation of both small molecule and macromolecular drugs including therapeutic, prophylactic and diagnostic agents, stabilizing agents and systems for their delivery. | 06-30-2011 |
20110165116 | PHARMACEUTICAL COMPOSITIONS COMPRISING CCL2 AND USE OF SAME FOR THE TREATMENT OF INFLAMMATION - A method of treating an inflammation in a subject thereof is provided. The method comprising administering to the subject a therapeutically effective amount of CCL2, thereby treating the inflammation. Also provided are pharmaceutical compositions and unit dosage forms which comprise CCL2 for the treatment of inflammation. | 07-07-2011 |
20110171168 | HUMAN G-CSF ANALOGS AND METHODS OF MAKING AND USING THEREOF - An analog of human granulocyte colony stimulating factor (hG-CSF analog) is disclosed. The hG-CSF analog comprises an amino acid sequence that differs from the wild-type hG-CSF sequence at position 17 and at least one other position, and is capable of preventing trophoblast cell apoptosis. Also disclosed is pharmaceutical compositions comprising the hG-CSF analog, polynucleotides encoding the hG-CSF analog, expression vectors containing the polynucleotides, host cells containing the expression vectors, as well as a method for preventing spontaneous abortion using the hG-CSF analog. | 07-14-2011 |
20110171169 | PEPTIDES FOR ACTIVE ANTI-CYTOKINE IMMUNIZATION - Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angstroms from an atom of the receptor corresponding to said cytokine, the spacing d being evaluated on the basis of structural data, derivatives, immunogenic compounds comprising them, use of a peptide or peptide derivative or immunogenic compound for the preparation of a curative or preventative medicament intended for the treatment or prevention of diseases linked to an excess or to the presence of cytokines or for the treatment of an auto-immune disease and pharmaceutical compositions which contain at least one abovementioned peptide or peptide derivative or immunogenic compound as active ingredient. | 07-14-2011 |
20110182847 | USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS - Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxicity) that may otherwise result in some patients of the TNF-R agonist is used as a monotherapy (without the type 1 interferon and/r TLR agonist). | 07-28-2011 |
20110182848 | GRANULOCYTE COLONY STIMULATING FACTOR - We disclose granulocyte colony stimulating factor fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said proteins. | 07-28-2011 |
20110189123 | MAMMALIAN CX3C CHEMOKINE ANTIBODIES - Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided. | 08-04-2011 |
20110189124 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES - The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins. | 08-04-2011 |
20110195043 | Dimeric Smac Mimetics - The invention provides small molecule mimics of the Smac peptide that are dimers or dimer-like compounds having two binding domains connected by a linker These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders. | 08-11-2011 |
20110200552 | CYTOKINE DESIGN - The present invention relates to novel cytokines, which have a modified selectivity/specificity for their cognate receptors. In particular, the invention relates to a variant TRAIL protein, which has superior selectivity for the death receptor 4 (TRAIL-RI) over the death receptor 5 (TRAIL-R2). In addition, the invention relates to a variant TRAIL protein which exhibits superior selectivity for the death receptor 4 (TRAIL-R1) over the decoy receptors DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4). | 08-18-2011 |
20110212051 | VARIANTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR AND USE THEREOF - Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention. Also provided are methods and kits for diagnosing, determining predisposition and/or prognosis of various disorders using as diagnostic markers the novel polypeptides and polynucleotides of the present invention. | 09-01-2011 |
20110212052 | METHODS AND COMPOSITIONS OF TREATING AND PREVENTING AUTOIMMUNE DISEASES - Provided are methods and compositions for treating and/or preventing an autoimmune diseases, including inflammatory bowel disease, rheumatoid arthritis, diabetes mellitus, celiac disease, autoimmune thyroid disease, autoimmune liver disease, Addison's Disease, Sjögren's Syndrome, transplant rejection, graft vs. host disease, or host vs. graft disease. | 09-01-2011 |
20110217258 | Combined Use of Bendamustine, Doxorubicin and Bortezomib for the Treatment of Multiple Myeloma - Methods for treating multiple myeloma by administering a combination of a proteasome inhibitor, bendamustine and doxorubicin are described. | 09-08-2011 |
20110250165 | Antibodies against CXCR4 and Methods of Use Thereof - The invention provides human monoclonal antibodies, scFv antibodies, scFv-Fc fusions, a dAb (domain antibodies), F | 10-13-2011 |
20110250166 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER - The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer. | 10-13-2011 |
20110256088 | TARGETED DELIVERY OF NUCLEIC ACIDS - Aspects of the invention provide compositions and methods for delivering nucleic acids to target cells. | 10-20-2011 |
20110256089 | Hydrogel Type Cell Delivery Vehicle for Wound Healing, and Preparation Method Thereof - Disclosed is a hydrogel type cell delivery vehicle composition for wound healing and to a preparation method thereof. More particularly, the present invention relates to a hydrogel type cell delivery vehicle composition in which non-ionic surfactants, growth factors or substance-P, human-derived cells, and the like are distributed in aqueous media, to a use thereof for wound healing, and to a preparation method thereof. The hydrogel type composition of the present invention appropriately delivers cells and/or substance-P to the wound part, and has moistening effects, effects of preventing contraction of the wound, and effects of protecting cells, and can be used in an easy and convenient manner. The cells in the composition are delivered to the wound part to effectively heal the wound when the composition of the present invention is applied to or injected into the wounded body part. | 10-20-2011 |
20110256090 | Method for Identifying Genes Involved in Trail-Induced Apoptosis and Therapeutic Applications Thereof - The invention relates to methods for identifying genes involved in TRAIL-induced apoptosis, to inhibitors of the expression of genes inducing resistance of cells to TRAIL-induced apoptosis and to activators of the expression of a gene sensitizing cells to TRAIL-induced apoptosis. The invention also relates to methods for sensitizing cells to TRAIL-induced apoptosis, methods for treating hyperproliferative diseases, methods for determining the responsiveness of a subject suffering from a hyperproliferative disease to TRAIL, to pharmaceutical compositions comprising products capable of sensitizing cells to TRAIL-induced apoptosis, and to methods for determining the prognosis of a subject suffering from a hyperproliferative disease. | 10-20-2011 |
20110262383 | Naphthalimide Dosing by N-Acetyl Transferase Genotyping - The present invention provides methods for dosing patients with naphthalimides, including amonafide, amonafide salts, and analogs thereof based on N-acetyl transferase genotyping. The invention also provides methods for dosing the amount of granulocyte colony stimulating factor (GCSF) used in combination with naphthalimide to prevent or modulate leukocytopenia. | 10-27-2011 |
20110268693 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis. | 11-03-2011 |
20110274646 | Compounds and Combinations - The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer. | 11-10-2011 |
20110280826 | Y-SHAPED POLYETHYLENE GLYCOL MODIFIED G-CSF, THE PREPARATION AND USE THEREOF - The present invention relates to granulocyte colony stimulating factor (G-CSF) modified with Y-shaped branched polyethylene glycol (YPEG-G-CSF) at a specific lysine (Lys 17) and the preparation thereof, as well as the pharmaceutical composition comprising YPEG-G-CSF and use thereof. | 11-17-2011 |
20110280827 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES - The invention relates to methods and compositions for treating a subject afflicted with a hematological malignancy using a combination of a CXCR4 antagonist and an immunotherapeutic agent. | 11-17-2011 |
20110286960 | CANCER THERAPY BY DOCETAXEL AND GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) - Neutropenia is the dose-limiting toxicity of the tri-weekly docetaxel (Taxotere®) schedule. Here, we evaluate in Metastatic Breast Cancer (MBC) patients (N=38) a computerized method for predicting docetaxel-induced neutropenia, and use the model to identify improved docetaxel and Granulocyte Colony Stimulating Factor (G-CSF) regimens. Pharmacokinetics/pharmacodynamics (PK/PD) models were created and simulated concomitantly with a mathematical granulopoiesis model. Individual baseline neutrophil counts and docetaxel schedules served as inputs. Our trial validated the model accuracy in predicting nadir timings (r=0.99), grade 3/4 neutropenia (86% success) and neutrophil profiles (r=0.62). Model was robust to CYP3A-induced variability, except for slightly less accurate grade 3/4 neutropenia predictions. Simulations confirm smaller toxicity of the weekly docetaxel regimen than the tri-weekly one, and suggest an optimal G-CSF support for alleviating neutropenia, 60 μg/day QD×3, 6-7 days post-docetaxel, administered tri- and bi-weekly, and 4 days post weekly docetaxel>33 mg/m | 11-24-2011 |
20110293554 | RECOMBINANT HUMAN G-CSF DIMER AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES - This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that function of injured nerves can be restored. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased. | 12-01-2011 |
20110293555 | TUMOR NECROSIS FACTOR-ALPHA MUTANTS - The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient. | 12-01-2011 |
20110293556 | TREATMENT OF INSULIN RESISTANCE/METABOLIC SYNDROME TO ALLEVIATE THE RISKS OF DEMENTIA - This invention relates to Applicant's discovery that Metabolic Syndrome , a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention further includes methods for the prevention or treatment of dementia and other neurological conditions based on (1) minimizing insulin resistance, thereby preventing excess biosynthesis of insulin; (2) modulating the activity of IDE such that insulin competes less efficiently with β-amyloid protein for the TDE; and (3) blocking the consequences of NMDA receptor activation, such as by minimizing the generation of NO and other harmful free radicals. | 12-01-2011 |
20110305661 | Carbazole Compounds and Therapeutic Uses of the Compounds - Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. | 12-15-2011 |
20110311472 | APPLICATION OF MRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES - The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer. | 12-22-2011 |
20110311473 | METHODS OF TREATING COGNITIVE IMPAIRMENT - The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment. | 12-22-2011 |
20120003178 | EVALUATING THE THERAPEUTIC POTENTIAL OF A GLUCAN - Provided herein are methods for predicting the response of a subject to administration of a glucan prior to said administration, comprising in one embodiment: isolating at least one cell from the subject, wherein the cell is capable of being stimulated by the glucan; contacting the at least one cell with the glucan and incubating for a period of time and under suitable conditions sufficient to stimulate the cell(s) thereby inducing a change in the level of expression, activity and/or secretion of one or more biomarkers from the cell(s); and determining the level of expression and/or secretion of the at least biomarker, wherein the level of expression, activity and/or secretion is predictive of the response of the subject to administration of the glucan. | 01-05-2012 |
20120003179 | ANTI-CTLA-4 AND CPG-MOTIF-CONTAINING SYNTHETIC OLIGODEOXYNUCLEOTIDE COMBINATION THERAPY FOR CANCER TREATMENT - The invention relates to administration of an anti-CTLA-4 antibody, particularly human antibodies to human CTLA-4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and MDX-010, in combination with an immunostimulatory nucleotide, i.e., CpG ODN PF3512676, for treatment of cancer. The invention relates to administering a combination of an anti-CTLA-4 antibody and CpG ODN PF3512676 as neoadjuvant, adjuvant, first-line, second-line, and third-line therapy of cancer, whether localized or metastasized, and at any point(s) along the disease continuum (e.g., at any stage of the cancer). | 01-05-2012 |
20120009139 | Methods and Compositions for Promoting Organ Development - Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or foetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof, or otherwise, at least one nucleic acid molecule encoding colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof. | 01-12-2012 |
20120014910 | COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS ASSOCIATED WITH MENOPAUSE, HORMONAL VARIATIONS AND ARTHRITIS - The invention provides for compositions and methods of treating or ameliorating menopausal symptoms and/or symptoms associated with hormonal variations by administering granulocyte colony-stimulating factor (G-CSF). The invention also provides for compositions and methods of treating or ameliorating arthritis using G-CSF. | 01-19-2012 |
20120020912 | PROSTATE CANCER VACCINE - Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines. | 01-26-2012 |
20120020913 | METHODS FOR PANCREATIC TISSUE REGENERATION - Disclosed are methods of expanding populations of pancreatic cells or inducing the generation of pancreatic progenitor cells in a subject or in culture using a therapeutically effective amount of a TWEAK receptor agonist. These methods may be used to treat diseases or conditions where enhancement of pancreatic progenitor cells for cell replacement therapy is desirable, including, e g, diabetes and conditions that result in loss of all or part of the pancreas | 01-26-2012 |
20120020914 | LEUKEMIA INHIBITORY FACTOR (LIF) FOR USE IN REPRESSING HUMAN PAPILLOMAVIRUS (HPV) TRANSCRIPTION - Embodiments of the invention are related to leukemia inhibitory factor (LIF) for use in repressing human papillomavirus (HPV) transcription. Processes and related kits are described for treating a HPV-associated papillomatous proliferation, for treating a HPV-associated genital, anal, vulvar, penile, oral, or laryngeal wart, for treating HPV-associated cervical dysplasia or cervical cancer, and for repressing HPV transcription, by administering LIF to a patient in need thereof. A related embodiment is treatment of HPV-16 by use of LIF. | 01-26-2012 |
20120034183 | COMPOSITIONS AND METHODS FOR GROWING EMBRYONIC STEM CELLS - Compositions including topical formulations comprising secreted products obtained from the culture medium of human embryonic germ (EG) cell derivatives and particular combinations of components therefrom are provided for treatment of various dermatological conditions, such as adverse consequences of aging, wrinkling, altered pigmentation, altered viscoelasticity, and altered thickness, among others. Methods for using the compositions and topical formulations for treating adverse or undesirable dermatological conditions are also provided, as well as preventing the appearance of undesirable dermatological conditions. | 02-09-2012 |
20120039839 | Hypoxia Induced Mitogenic Factor - We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II. | 02-16-2012 |
20120045411 | SHORT BETA-DEFENSIN-DERIVED PEPTIDES - The invention is directed to beta-defensin-derived peptides and their use in modulating the activity of hematopoietic cells and other CXCR4-expressing cells. Specifically, the invention provides compositions and methods useful in the treatment of cancer. The invention further provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. | 02-23-2012 |
20120045412 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS - The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 02-23-2012 |
20120064028 | Pregnancy-Induced Oligodendrocyte Precursor Cell Proliferation Regulated by Prolactin - The present invention relates to a method to increase oligodendrocytes and oligodendrocyte precursor cells through administration of prolactin or a prolactin inducing agent. | 03-15-2012 |
20120064029 | COMPOSITIONS FOR TREATING NERVOUS SYSTEM CONDITIONS - Compositions for treating nervous system conditions. In at least one embodiment of a stem cell conditioned medium of the present disclosure, the stem cell comprises a cell culture supernatant containing at least one factor capable of exerting effective neuroprotection to treat a mammalian neural injury or insult, the cell culture supernatant produced by culturing at least one mammalian adipose stem cell to produce the at least one factor. | 03-15-2012 |
20120064030 | METHODS OF TREATING NERVOUS SYSTEM CONDITIONS - Methods of treating nervous system conditions. In at least one embodiment of a method of treating a mammalian patient having a neuronal injury or insult of the present disclosure, the method comprises the step of administering a therapeutically-effective dose of a stem cell conditioned medium to a mammalian patient, the stem cell conditioned medium comprising a cell culture supernatant containing at least one factor capable of exerting effective neuroprotection to treat a mammalian neural injury or insult. | 03-15-2012 |
20120070403 | USE OF G-CSF FOR THE EXTENSION OF THE THERAPEUTIC TIME-WINDOW OF THROMBOLYTIC STROKE THERAPY - The present invention relates to the use of G-CSF and derivatives thereof for extending the therapeutic window of subsequent thrombolytic treatment of acute stroke, and thereby, allowing the diagnostic examinations which are necessary prior to the thrombolytic treatment in order to avoid hemorrhagic and other severe adverse side effects of the thrombolysis. | 03-22-2012 |
20120076752 | Mesothelin Vaccines and Model Systems - Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line. | 03-29-2012 |
20120082640 | Small molecule apoptosis promoters - The invention provides small molecule mimics of the Smac peptide that are dimer- or dimer-like compounds having two amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders. | 04-05-2012 |
20120082641 | FORMULATIONS FOR BOVINE GRANULOCYTE COLONY STIMULATING FACTOR AND VARIANTS THEREOF - This invention provides stable aqueous formulations comprising a bG-CSF polypeptide or a variant thereof, a buffer substance, and an excipient, wherein said formulation is substantially free of polyoxyethylene (20) sorbitan monolaurate. The invention also provides methods of using, a lyophilized or powdered form of, and processes for, preparing the formulation. | 04-05-2012 |
20120082642 | Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors - A method for treating adult onset neurodegenerative diseases and diabetes by administering an effective dose of Granulocyte-Colony Stimulating Factors. | 04-05-2012 |
20120093764 | TREATMENT OF DIABETES USING G-CSF AND HYPERBARIC OXYGEN - A method of treating endothelial cells comprising: inducing vasodilation in a patient; and administering a composition including a stem cell proliferation agent to the patient. | 04-19-2012 |
20120093765 | PROCESS FOR PURIFICATION OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR - The present invention describes a novel process for large-scale purification of therapeutic grade quality of recombinant human GCSF from microbial cells, wherein the protein is expressed as inclusion bodies. The Inclusion bodies are solubilized and refolded under redox condition. The Redox condition is provided by using ascorbic acid, dehydroascorbic acid and reduced gluthathione. The process involves the novel use of aqueous two phase extraction step to purify refolded GCSF after removal of denaturant. After this step GCSF is further purified using chromatography techniques for removal of related impurities. The GCSF obtained has good purity and yields which are essential for a production scale process. The host cell related contaminants like proteins, DNA and endotoxins are reduced using the purification processes of the invention. | 04-19-2012 |
20120100099 | FUSION PROTEINS HAVING MUTATED IMMUNOGLOBULIN HINGE REGION - A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue located nearest the cysteine residue of the non-Ig component. The distance from the cysteine residue of the non-immunoglobulin polypeptide and any remaining cysteine residues of the mutated hinge region is sufficient to prevent the formation of a disulphide bond therebetween. | 04-26-2012 |
20120114593 | METHOD AND COMPOSITION FOR ALTERING A B CELL MEDIATED PATHOLOGY - The present invention provides compositions for altering a B cell mediated pathology in a patient. The compositions may comprise at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the V | 05-10-2012 |
20120114594 | MUSCLE REPAIR PROMOTER - The present invention relates to muscle repair promoters for topical application that contain a colony-stimulating factor (CSF) as an active ingredient. The muscle repair promoters of the present invention exhibit their effect at low doses, particularly when they are administered intramuscularly. | 05-10-2012 |
20120114595 | SUGAR CHAIN-ADDED AILIM EXTRACELLULAR DOMAIN AND METHOD FOR PRODUCING SAME - Disclosed is a synthetic AILIM extracellular domain which has high ligand-binding ability and a quality sufficient for a pharmaceutical product. Also disclosed is a method for synthesizing the synthetic AILIM extracellular domain. Specifically disclosed is a sugar chaim-added AILIM extracellular domain wherein a sugar chain is bound at a position corresponding to the 69-position of the amino acid sequence of human AILIM extracellular domain, said amino acid sequence being depicted in SEQ ID NO: 7, and no sugar chain is added at positions corresponding to the 3-position and the 90-position of the amino acid sequence. | 05-10-2012 |
20120121535 | AGENT FOR PREVENTING RECURRENCE OF LEUKEMIA - The present invention provides a drug capable of initiating the progression of the cell cycle of leukemia stem cells to overcome the resistance of the leukemia stem cells to cell cycle-dependent chemotherapeutic agents, and a drug for suppressing recurrence of leukemia containing the same, and the like, an agent containing G-CSF, wherein the agent is for inducing the progression of the cell cycle of leukemia stem cells, a drug for suppressing recurrence of leukemia containing a combination of G-CSF and a cell cycle-dependent antitumor agent, and the like. | 05-17-2012 |
20120128624 | Recombinant Human Albumin-Granulocyte Macrophage Colony Stimulating Factor Fusion Protein With Long-Lasting Biological Effects - Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast. | 05-24-2012 |
20120134954 | DEFENSIN-ANTIGEN FUSION PROTEINS - The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection. | 05-31-2012 |
20120148526 | STRONGLY INACTIVATED AND STILL HIGHLY IMMUNOGENIC VACCINE AND PROCESS OF MANUFACTURING THEREOF - An immunogenic product includes TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A. An emulsion and a vaccine including the immunogenic product and methods for preparing the immunogenic product are also described. | 06-14-2012 |
20120148527 | TNF Superfamily Fusion Proteins - The present invention refers to fusion proteins comprising a TNF superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a trimerization domain and a nucleic acid molecule encoding the fusion protein. The fusion protein is present as a trimeric complex or as an oligomer thereof and is suitable for therapeutic, diagnostic and/or research applications. | 06-14-2012 |
20120189572 | VACCINES TARGETING CELLULAR DEATH RECEPTORS - The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family. Also provided are means and methods for overcoming host immunological tolerance to death receptors. The vaccines are useful against cancer cells and other death receptor bearing target cells within the host, and can be used in both therapeutic and prophylactic settings. The vaccines are also useful for diagnostic testing of the immunocompetence of a host. | 07-26-2012 |
20120189573 | Methods of using death receptor agonists and EGFR inhibitors - Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and EGFR inhibitors to treat pathological conditions such as cancer are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with EGFR inhibitors, such as Tarceva™. | 07-26-2012 |
20120189574 | METHODS FOR HEMATOPOIETIC PRECURSOR MOBILIZATION - Methods of modulating mobilization of cells from the bone marrow are provided. In a specific embodiment there is provided a method of increasing mobilization of hematopoietic precursors from the bone marrow to the peripheral blood in a subject in need thereof, the method comprising: (a) administering to the subject an agent which downregulates an activity or expression of a coagulation factor or an effector thereof; and (b) harvesting the hematopoietic precursors from the peripheral blood. | 07-26-2012 |
20120189575 | Oligodendrocyte Production from Multipotent Neural Stem Cells - This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor. | 07-26-2012 |
20120195851 | MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS WITH IMPROVED BIOLOGICAL ACTIVITY - The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules. | 08-02-2012 |
20120213728 | GRANULOCYTE-COLONY STIMULATING FACTOR PRODUCED IN GLYCOENGINEERED PICHIA PASTORIS - Compositions comprising granulocyte-colony stimulating factor (GCSF) produced in a strain of | 08-23-2012 |
20120225028 | COMPOSITIONS AND METHODS FOR MOBILIZATION OF STEM CELLS - The present invention relates to mobilization of stem cells. In particular, the present invention relates to growth factor-induced mobilization of stem cells in vivo for collection or tissue repair. | 09-06-2012 |
20120230939 | METHODS FOR TREATING CANCER USING PROSTATE SPECIFIC ANTIGEN AND TUMOR ENDOTHELIAL MARKER PEPTIDES - The present invention is directed to prostate specific antigen (PSA) and tumor endothelial marker 8 (TEM8) peptide compositions and methods for treating cancer with the compositions. | 09-13-2012 |
20120230940 | CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE - Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. | 09-13-2012 |
20120230941 | Methods for treating nervous system injury and disease - The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents. | 09-13-2012 |
20120237472 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES USING IMMUNOMODULATORY AGENTS - The present invention provides compositions and methods for treating and/or preventing an autoimmune disease comprising administering to a subject in need thereof an effective amount of cyclophosphamide and/or a cyclophosphamide derivative in combination with an additional immunomodulatory agent. | 09-20-2012 |
20120237473 | Compositions And Methods For Cell Based Retinal Therapies - The invention relates to pharmaceutical compositions comprising trophic factors, methods to decrease the degeneration of a retina, methods of treating ocular degenerative diseases and methods to select cells for transplantation. | 09-20-2012 |
20120244110 | FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 - Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: | 09-27-2012 |
20120244111 | Pheromones and the Luteinizing Hormone for Inducing Proliferation of Neural Stem Cells and Neurogenesis - The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions. | 09-27-2012 |
20120251485 | ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN SIGLEC-15 - To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like. | 10-04-2012 |
20120251486 | MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME - The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to be coupled to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved resistance against in vivo protease activity, and thus exhibit improved bioavailability and an improved absorption rate. | 10-04-2012 |
20120258070 | Methods and Compositions for Promoting Organ Development - Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or fetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof, or otherwise, at least one nucleic acid molecule encoding colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof. | 10-11-2012 |
20120258071 | Compositions and Methods of Use for MGD-CSF in Disease Treatment - Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss. | 10-11-2012 |
20120263673 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF PREECLAMPSIA - Methods and kits for preventing or reducing the likelihood of implantation failure or miscarriage in a recipient of artificial insemination are provided. The methods include administering into a recipient of artificial insemination in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF). | 10-18-2012 |
20120263674 | PSEUDOMONAS EXOTOXIN A WITH REDUCED IMMUNOGENICITY - The present invention provides improved | 10-18-2012 |
20120263675 | BIVALENT DIAZO BICYCLIC SMAC - The invention relates to diazo bicyclic Smac mimetics that are tethered through a covalent linker to give a bivalent species. Bivalent diazo bicyclic Smac mimetics function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs). The invention also relates to the use of bivalent diazo bicyclic Smac mimetics for inducing or sensitizing cells to the induction of apoptotic cell death. Thus, compounds of the invention are useful in the treatment, amelioration, or prevention of hyperproliferative diseases such as cancer. | 10-18-2012 |
20120269763 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF PRETERM LABOR - The present invention provides compositions, kits and methods for the prevention of spontaneous abortion or implantation failure during assisted reproduction. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent spontaneous abortion or implantation failure of an embryo. The present invention also provides compositions, kits and methods for the treatment or prevention of preeclampsia and preterm labor. | 10-25-2012 |
20120276042 | DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS, AND METHODS OF USE THEREOF - The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention. | 11-01-2012 |
20120276043 | IMMUNOGLOBULIN FUSION PROTEINS - Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules. | 11-01-2012 |
20120276044 | METHOD FOR INDUCING MIGRATION OF ADIPOSE-DERIVED ADULT STEM CELLS - The present invention relates to the ability of adipose tissue-derived adult stem cells to migrate, and more particularly to the novel use of adipose tissue-derived adult stem cells primed with a specific chemokine or growth factor and their specific secretory products, which more effectively migrate to a disease site in vivo. The inventive composition containing either adipose-derived adult stem cells or adipose tissue-derived adult stem cells primed with a specific chemokine or growth factor can be administered by a simple method such as intravenous administration and are able to induce the targeting of the stem cells to a disease site. Thus, the composition is useful as a cell therapeutic agent. | 11-01-2012 |
20120288472 | REGULATION OF T CELL-MEDIATED IMMUNITY BY TRYPTOPHAN - A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and other types of transplantation. Inhibitors of IDO can be used to activate T cells. Inhibiting tryptophan degradation, or supplementing tryptophan concentration, can be used in addition to, or in place of, inhibitors of IDO. Increasing tryptophan degradation (thereby, decreasing tryptophan concentration and increasing tryptophan metabolite concentration), for example, by increasing IDO concentration or IDO activity, can suppress T cells. One can manipulate local tryptophan concentrations, and/or modulate the activity of the high affinity tryptophan transporter, and/or administer tryptophan degrading enzymes. Regulation can be further manipulated using cytokines such as MCSF, IFNγ, alone or in combination with antigen or other cytokines. | 11-15-2012 |
20120294829 | LIQUID FORMULATIONS FOR LONG-ACTING G-CSF CONJUGATE - Disclosed is a liquid formulation which allows long-acting G-CSF conjugates, that have improved in vivo duration and stability, to be stable when stored for a long period of time. It comprises a stabilizer composition characterized by buffer and mannitol. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting G-CSF conjugates. | 11-22-2012 |
20120301425 | NOVEL ANTITUMORAL USE OF CABAZITAXEL - The invention relates to a compound of formula: | 11-29-2012 |
20120301426 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS - The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 11-29-2012 |
20120308513 | PROMISCUOUS HER-2/NEU CD4 T CELL EPITOPES - The present invention relates to the discovery of novel T cell epitopes of the human HER-2/Neu protein that is promiscuous for at least 25 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such a epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides. | 12-06-2012 |
20120315243 | METHODS AND KITS FOR REDUCING THE LIKELIHOOD OF IMPLANTATION FAILURE AND PREGNANCY-RELATED DISORDERS IN RECIPIENTS OF ARTIFICIAL INSEMINATION - Methods and kits for preventing or reducing the likelihood of implantation failure or miscarriage in a recipient of artificial insemination are provided. The methods include administering into a recipient of artificial insemination in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF). | 12-13-2012 |
20120315244 | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Inhibiting Gene Products - The present disclosure relates to methods for the modulation of autophagy and the treatment of autophagy-related diseases, including cancer, neurodegenerative diseases and pancreatitis. | 12-13-2012 |
20120321589 | Antibody Fusion Proteins with Disrupted Heparin-Binding Activity - Disclosed herein are polypeptides which comprise all or part of an antibody linked to all or part of a cytokine. The cytokine sequences of the polypeptides have a modified heparin binding region which disrupts, inhibits, or reduces the ability of the cytokine to bind a heparin compound as compared to a corresponding cytokine having an unmodified heparin binding region. Also disclosed are methods of treating cancer, inducing cell proliferation, and reducing the non-specific binding and/or non-specific localization of the polypeptides. | 12-20-2012 |
20120328557 | ADHESIVE CELL TISSUE GELS - Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent. | 12-27-2012 |
20120328558 | ANTIBODY-LIGHT FUSION PRODUCTS FOR CANCER THERAPEUTICS - Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases. | 12-27-2012 |
20120328559 | Compositions and Methods for Treating Inflammatory Lung Disease - The invention provides a method of modulating a T cell immune response by modulating DR3 function in the T cell, wherein the T cell response causes a symptom of inflammatory lung disease. The invention also provides a method of treating a reactive airway disease in an animal subject by administering to the subject an agent which modulates at least one functional activity of CD30. The invention additionally provides a method for treating an inflammatory lung disease by administering an agent that decreases the activity of DR3 or CD30, whereby IL-13 expression is decreased. | 12-27-2012 |
20120328560 | METHOD FOR OBTAINING BIOLOGICALLY ACTIVE RECOMBINANT HUMAN G-CSF - Provided is a method of obtaining biologically active recombinant human G-CSF from inclusion bodies, wherein the solubilization and refolding process can be performed at ambient temperature and the purification step comprises reversed phase chromatography (RP), in particular RP-HPLC. The G-CSF preparation so obtained is characterized by high purity and homogeneity. | 12-27-2012 |
20130004456 | COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas. | 01-03-2013 |
20130039882 | METHOD TO MITIGATE INJURY FROM RADIATION EXPOSURE - Mitigating radiation induced injury to a mammal that has been exposed to radiation by administering a pharmaceutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal. | 02-14-2013 |
20130039883 | METHOD OF SENSITIZING CANCER CELLS TO THE CYTOTOXIC EFFECTS OF DEATH RECEPTOR LIGANDS IN CANCER TREATMENT - Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with a death receptor ligand, which method comprises contacting the cancer cells with a death receptor ligand in conjunction with an effective amount of a compound described herein, for example, a cucurbitacin (I) or a withanolide (II). Also disclosed is a method of inducing apoptosis in cancer cells in a mammal, comprising contacting the cancer cells with a compound described herein, for example, a cucurbitacin (I) or a withanolide (II) and also contacting the cancer cells with a death receptor ligand, whereby apoptosis is induced in the cancer cells. | 02-14-2013 |
20130045179 | Combination therapy and methods for treatment and prevention of hyperproliferative diseases - The present invention provides therapy and methods for the treatment and prevention of diseases of cell proliferation such as cancer, benign tumors, and viral diseases such as HIV-AIDS, hepatitis B, hepatitis C and cirrhosis. The methods of this invention consist of the administration to a patient of a combination of effective amounts of agents capable of eradicating the neoplastic cells, while sparing the non-neoplastic cells from cytotoxic side-effects. The agents co-administered in therapeutically effective amounts are: chemotherapeutic agents, apoptotic agents, anti-angiogenic agents, cell differentiation agents, immunomodulating agents, antioxidants, vitamins, microelements, enzymes and natural extracts. | 02-21-2013 |
20130058891 | Kexin-Derived Vaccines to Prevent or Treat Fungal Infections - A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as | 03-07-2013 |
20130058892 | PYRIMIDINYL INDOLE COMPOUNDS - The present invention provides pyrimidinyl indole compounds as novel kinase inhibitors for the treatment of cancer and inflammatory diseases. | 03-07-2013 |
20130058893 | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof - Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided. | 03-07-2013 |
20130071350 | METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS - The present invention refers to a system for inducing an immune response against transformed, infected, or diseased tissue comprising a device for removing only components present in blood or plasma having a molecular weight of 120,000 daltons or less, having an inlet and outlet for connection to a pump and tubing to recirculate the blood or plasma of a patient through the device. Further, the present invention refers to methods of inducing an immune response against transformed, infected, or diseased tissue comprising administering to a patient blood, plasma, or a blood fraction from which only components having a molecular weight of 120,000 daltons or less have been removed, whereby administration of said blood, plasma, or blood fraction induces an immune response against transformed, infected, or diseased tissue in the patient until the transformed, infected, or diseased tissue is reduced in amount. | 03-21-2013 |
20130089513 | METHOD OF IMPROVING EFFICACY OF BIOLOGICAL RESPONSE-MODIFYING PROTEINS AND THE EXEMPLARY MUTEINS - Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate. Also, the present invention discloses a DNA encoding the protein variant, a recombinant expression vector to which the DNA is operably linked, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing the protein variant comprising cultivating the host cell and isolating the protein variant from the resulting culture. Further, the present invention discloses a pharmaceutical composition comprising the protein variant and a pharmaceutically acceptable carrier. | 04-11-2013 |
20130089514 | Stem cell secreted product derived compositions for wound treatment - Compositions including formulations comprising secreted products obtained from the culture medium of stem cells, such as umbilical cord blood stem cells, or embryonic germ cell derivatives, or embryonic stem cells, are provided for enhancement of wound healing. Further compositions contain components identified in such culture medium to enhance wound healing. Methods for using the compositions and formulations for enhancing wound healing are also provided. Wounds to both soft and bony tissues are encompassed, and include wounds created by surgical procedures. | 04-11-2013 |
20130095060 | PHARMACEUTICAL COMPOSITION FOR PROMOTING ARTERIOGENESIS, AND PREPARATION METHOD AND APPLICATIONS FOR THE SAME - The present invention relates to a pharmaceutical composition for promoting arteriogenesis, and preparation method and applications of the same, wherein said pharmaceutical composition comprises an effective amount of a drug, and a peptide hydrogel, and it forms a microenvironment for autologous cell recruitment and tissue regeneration. | 04-18-2013 |
20130095061 | UMBILICAL CORD STEM CELL SECRETED PRODUCT DERIVED TOPICAL COMPOSITIONS AND METHODS OF USE THEREOF - Compositions including topical formulations comprising secreted products obtained from the culture medium of human umbilical cord stem cells and particular combinations of components therefrom are provided for treatment of various dermatological conditions, such as adverse consequences of aging, wrinkling, altered pigmentation, altered viscoelasticity, and altered thickness, among others. Methods for using the compositions and topical formulations for treating adverse or undesirable dermatological conditions are also provided, as well as preventing the appearance of undesirable dermatological conditions. | 04-18-2013 |
20130101549 | LIGHT TARGETING MOLECULES AND USES THEREOF - LIGHT-targeting molecules (e.g., LIGHT fusion molecules), compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided. | 04-25-2013 |
20130108578 | APO-2 LIGAND VARIANTS AND USES THEREOF | 05-02-2013 |
20130108579 | METHODS OF USING SMALL COMPOUNDS TO ENHANCE MYELOID DERIVED SUPPRESSOR CELL FUNCTION FOR TREATING AUTOIMMUNE DISEASES | 05-02-2013 |
20130108580 | FUSION PROTEIN AND ITS USES | 05-02-2013 |
20130115188 | COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GASTRIC CANCER AND OTHER CANCERS - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gastric cancers (GC). | 05-09-2013 |
20130121956 | Composition for Enhancing Bone Formation - Disclosed herein is a matrix for inducing or enhancing osteoclast differentiation. The matrix comprises a material having an osteoclastogenic agent associated therewith, the agent being releasable from the material in an amount which is sufficient to induce or enhance osteoclast differentiation. | 05-16-2013 |
20130129668 | Diagnosis and treatment of arthritis using epigenetics - Embodiments of the present invention include methods, compositions and kits for evaluating a diagnosis, prognosis, or response to treatment of a subject with a disorder such as rheumatoid arthritis or osteoarthritis. Some embodiments include identifying a therapeutic agent for treating a disorder such as rheumatoid arthritis or osteoarthritis. | 05-23-2013 |
20130129669 | Stable Formulations of Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor - Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described. | 05-23-2013 |
20130136717 | THERAPEUTIC USE OF AGONISTS OR ANTAGONISTS OF BRADYKININ RECEPTOR 1 OR 2, FOR MODULATION COLLATERAL BLOOD VESSEL GROWTH - The present invention relates to bradykinin receptor modulators and pharmaceutical compositions thereof for use as a medicament for modulating collateral blood vessel growth of collateral arteries and/or other blood vessels of pre-existing arterial networks. The bradykinin receptor modulators of arteriogenesis are applicable in the treatment and/or prevention of disorders associated with defective blood flow or blood vessel malformation. A preferred aspect of the invention relates to bradykinin receptor agonists for use as a medicament for the prevention of cardiovascular ischemic disease in a patient at risk thereof. Further, the invention relates to a bradykinin receptor agonist for use in a method for treating a cardiovascular ischemic disease in a patient in need thereof, wherein said cardiovascular ischemic disease is a peripheral limb disease. | 05-30-2013 |
20130156726 | ENDOMETRIAL STEM CELLS AND METHODS OF MAKING AND USING SAME - The invention provides pluripotent stem cells and methods for making and using pluripotent stem cells. Pluripotent stem cells, among other things, can differentiate into various cell lineages in vitro, ex vivo and in vivo. Pluripotent stem cells, among other things, can also be used to produce conditioned medium. | 06-20-2013 |
20130164251 | MUTANT G-CSF FUSION PROTEIN, AND PREPARATION AND USE THEREOF - The present invention relates to a mutant G-CSF fusion protein. The mutant G-CSF fusion protein is a fusion protein having the activity of stimulating the proliferation of neutrophilic granulocytes, and having a basic structure of G-CSF/carrier protein or carrier protein/G-CSF; wherein the G-CSF moiety comprises multipoint substitutions thus resulting in changes in biological activity and binding affinity. Compared with existing products, the mutant G-CSF fusion protein in the present invention has longer half-life and higher biological activity. Administration of the pharmaceutical preparation containing this mutant G-CSF fusion protein could be used in the treating neutropenia. | 06-27-2013 |
20130164252 | Method for Hair Growth using Granulocyte-Colony Stimulating Factor - The present invention provides a method for re-growing hair in patients with androgenic alopecia by administering effective consecutive courses of Granulocyte-Colony Stimulating Factor or derivatives. After the state of re-growth is obtained, the hair growth is maintained by administering periodic courses of Granulocyte-Colony Stimulating Factor or derivatives. The invention further provides a method for increasing cuticle growth and density using a similar administration of effective consecutive courses of Granulocyte-Colony Stimulating Factor or derivatives. The increased cuticle growth and density is maintained by administering periodic courses of Granulocyte-Colony Stimulating Factor or derivatives. | 06-27-2013 |
20130164253 | Long-Term Storage of Non-Glycosylated Recombinant Human G-CSF - The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing the non-glycosylated recombinant human G-CSF and sorbital is cooled to a temperature of −15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state and then increased in temperature to a temperature within the range of from 2° C. to 8° C. for a period of time adjusted to allow the composition to thaw and to obtain a liquid composition having a G-CSF content of at least 95% of the G-CSF content of the original composition. | 06-27-2013 |
20130164254 | ANTICANCER FUSION PROTEIN - The fusion protein, especially recombinant, comprising domain (a) which is a functional fragment of soluble hTRAIL protein sequence beginning with an amino acid at a position not lower than hTRAIL95 or a sequence having at least 70% homology thereto; and domain (b) which is a sequence of pro-apoptotic effector peptide, wherein the sequence of domain (b) is attached at C-terminus and/or N-terminus of domain (a). The fusion protein has anticancer activity. The nucleotide sequence coding the fusion protein, expression vector and host cell for the preparation of the fusion protein, and the use of the fusion protein for treating cancer diseases. | 06-27-2013 |
20130189223 | Methods and Compositions for Promoting Renal Repair and Regeneration - Methods and compositions comprising CSF-1 are provided for regenerating, repairing or otherwise treating renal cells, tissues and/or organs, and more particularly, in prophylactic or therapeutic treatment of diseases or conditions associated with renal damage and/or dysfunction. In particular, CSF-1 may be particularly efficacious in treating acute renal failure. CSF-1 protein or an encoding nucleic acid may be administered to suppress, ameliorate or otherwise treat an existing renal disease or condition or to prevent, inhibit, suppress or otherwise protect against subsequent renal damage and/or renal failure. CSF-1 may also be used to regenerate or repair renal cells, tissue and/or organs ex vivo, the treated cells, tissue and/or organs then being suitable for subsequent transplantation to an animal, such as a human. Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or foetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof, or otherwise, at least one nucleic acid molecule encoding colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof. | 07-25-2013 |
20130202552 | BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUADROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS - The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membrane signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence. | 08-08-2013 |
20130209393 | THERAPEUTIC PEPTIDE COMPOSITIONS AND METHODS - Therapeutic peptide compositions comprise a therapeutic peptide, such as insulin, together with an alkyl N,N-disubstituted amino acetate, such as dodecyl 2-(N,N-dimethylamino) propionate. | 08-15-2013 |
20130216495 | PHARMACEUTICAL COMPOSITION COMPRISING CD34+ CELLS - The invention relates to the field of treatment of ischemic conditions and diseases using a cell population comprising CD34+ cells isolated from peripheral blood of a subject. The invention provides a pharmaceutical composition comprising (i) a cell population comprising CD34+ cells, (ii) a plasma protein, and (iii) an isotonic solution comprising at least one salt, said isotonic solution comprising acetate, gluconate, or both acetate and gluconate. Methods of treating tissue damaged by ischemia in a subject and methods of treating a medical condition, wherein the pharmaceutical composition of the invention is administered, are further provided herein. Also, methods of promoting mobilization of CD34+ cells from bone marrow into peripheral blood are provided herein. | 08-22-2013 |
20130216496 | METHODS FOR TREATING TWEAK-RELATED CONDITIONS - The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists. | 08-22-2013 |
20130224144 | SEQUENTIAL ADMINISTRATION OF A REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION PROTOCOLS - Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided. | 08-29-2013 |
20130224145 | COMPLEX HAVING TUMOR VACCINE EFFECT, AND USE THEREOF - The present invention provides a tumor cell-soluble TNF family member molecule complex containing a tumor cell and an isolated soluble TNF family member molecule, wherein the soluble TNF family member molecule is bound on a surface of the tumor cell such that it binds to a receptor of the TNF family member expressed on a surface of a cell other than the tumor cell, and stimulates the cell other than the tumor cell via the receptor, and a composition and a tumor vaccine, each containing the complex. | 08-29-2013 |
20130230483 | FUSION MOLECULE BASED ON NOVEL TAA VARIANT - This invention provides novel carbonic anhydrase (CAIX) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a CAIX antigenic marker. The novel CAIX variant and related compositions are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, adoptive immunotherapy. | 09-05-2013 |
20130251668 | USE OF OSTEOPROTEGERIN (OPG) TO INCREASE HUMAN PANCREATIC BETA CELL SURVIVAL AND PROLIFERATION - It is disclosed herein that osteoprotegerin increases human beta cell proliferation and survival. Methods are provided for increasing beta cell proliferation, but contacting a beta cell with an effective amount of osteoprotegrin, a functional fragment, variant or fusion protein thereof. Methods are also provided for treating a human subject with diabetes, comprising administering to the subject a therapeutically effective amount of osteoprotegerin, functional variant or fusion protein thereof. | 09-26-2013 |
20130251669 | TREATMENT OF DIABETES USING G-CSF AND HYPERBARIC OXYGEN - A method of treating endothelial cells comprising: inducing vasodilation in a patient; and administering a composition including a stem cell proliferation agent to the patient. | 09-26-2013 |
20130259824 | Treatment for Ischemic Stroke - Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent. | 10-03-2013 |
20130259825 | Method for Enhancing Umbilical Cord Blood Engraftment - A method for enhancing bone marrow cells, peripheral blood, and umbilical cord blood engraftment is disclosed wherein at least one of a granulocyte colony stimulating factor and a granulocyte macrophage colony stimulating factor, and optionally romiplostim, and optionally an erythropoiesis-stimulating agent, are added thereto for enhancing the engraftment of CD44 cells within the bone marrow cells, peripheral blood, and umbilical cord blood. Also provided is a method for enhancing a stem cell infusion by activating an up-regulation of a AF1q/CD44 signaling pathway. A stem cell product is disclosed having treated stem cells conditioned for activating an up-regulation of a AF1q/CD44 signaling pathway. | 10-03-2013 |
20130272998 | POLYNUCLEOTIDE CONSTRUCTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TARGETED DOWNREGULATIONS OF ANGIOGENESIS AND ANTICANCER THERAPY - A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth. | 10-17-2013 |
20130272999 | Epidermal Growth Factor Composition, A Process Therefor and Its Application - A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant. | 10-17-2013 |
20130280205 | Activators of SGK-1 for Use as Cardioprotective Agents - Compositions for activating SGK-1 are provided. SGK-1 activators can be identified by the methods of screening provided herein. The SGK-1 activators can be used in the disclosed methods of reducing cell death and methods of treating ischemic-reperfusion injury. The ischemic-reperfusion injury can be due to a variety of complications resulting in blood loss to tissue and then the re-establishment of blood flow to the tissue. | 10-24-2013 |
20130280206 | STABILIZED POLYMERIC THIOL REAGENTS - Disclosed are water soluble polymeric conjugates comprising the structure POLY-[Y—S—S-A] | 10-24-2013 |
20130280207 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF SPONTANEOUS ABORTION IN A HUMAN FEMALE - Methods and kits for preventing or reducing the likelihood of implantation failure or miscarriage in a recipient of artificial insemination are provided. The methods include administering into a recipient of artificial insemination in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF). | 10-24-2013 |
20130287728 | Compositions and Methods for Treating Progressive Myocardial Injury Due to A Vascular Insufficiency - The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent. The method treats ongoing vascular insufficiency affecting coronary circulation by (i) stimulating neoangiogenesis in a peri-infarct border zone, thereby improving myocardial perfusion; and, (ii) through a paracrine effect, preventing apoptosis of cardiomyocytes in the peri-infarct border zone. The neoangiogenesis and paracrine-mediated reduction of apoptosis reduces progressive myocardial cell loss, which leads to improvement in cardiac function and a reduction of risk of major adverse cardiovascular events. | 10-31-2013 |
20130302270 | TUMOR TARGETED TNF-RELATED APOPTOSIS INDUCING LIGAND FUSION POLYPEPTIDE, METHODS AND USES THEREFOR - Fusion polypeptides comprising a TRAIL trimer and a targeting domain are disclosed. The targeting domain can be, in some embodiments, a sequence that binds MUC16, which is prevalent on some tumor cells such as pancreatic and ovarian tumor cells. A sequence that binds MUC 16 can be mesothelin or a MUC16-binding fragment thereof, such as amino acids 1-64 of mesothelin. A fusion polypeptide of the present teachings can induce apoptosis in a target cell such as a MUC16-expressing cancer cell. Also disclosed are nucleic acids encoding the fusion polypeptides, and methods of use of the fusion polypeptides and nucleic acids. | 11-14-2013 |
20130302271 | MUSCLE REPAIR PROMOTER - The present invention relates to muscle repair promoters for local application that contain a colony-stimulating factor (CSF) as an active ingredient. The muscle repair promoters of the present invention exhibit their effect at low doses, particularly when they are administered intramuscularly. | 11-14-2013 |
20130302272 | THERAPEUTIC AGENTS FOR MUSCULAR DYSTROPHY - The present invention provides therapeutic agents for diseases associated with skeletal muscle degeneration comprising a granulocyte colony-stimulating factor (G-CSF) as an active ingredient. The therapeutic agents of the present invention are especially effective as therapeutic agents for muscular dystrophy. | 11-14-2013 |
20130309193 | COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas. | 11-21-2013 |
20130315856 | CONJUGATES FOR THE TREATMENT OF MESOTHELIOMA - The present invention provides conjugates of cytokines and targeting peptides that is able to bind to a receptor expressed on tumor-associated vessels or to a component of the extracellular matrix associated to the tumor vessels, for treatment of malignant pleural mesothelioma. In particular, the invention provides conjugates comprising the cytokine TNF linked to a peptide containing the NGR motif. The invention further provides pharmaceutical compositions comprising such conjugate and pharmaceutical formulations comprising conjugates dissolved in appropriate buffers. | 11-28-2013 |
20130315857 | Kexin-Derived Vaccines to Prevent or Treat Fungal Infections - A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as | 11-28-2013 |
20130323196 | METHOD FOR MOBILIZING STEM AND/OR PROGENITOR CELLS - The present disclosure relates to methods for mobilizing stem and/or progenitor cells which are VLA-4 positive to the peripheral blood of a subject or from a tissue. The method comprises administering to the subject or tissue an effective amount of an antisense compound to VLA-4. | 12-05-2013 |
20130323197 | IFG-1 DEPENDENT MODULATION OF VSELS - Characteristics of the VSELs stem cell population of a mammal are correlated with aging, including VSEL number, imprinting status of genetic loci, and expression of markers of pluripotent stem cells. The present invention provides VSEL-based methods and compositions for determining the biological age of a mammal. | 12-05-2013 |
20130323198 | Use of AMG 900 for the Treatment of Cancer - The present invention relates to methods of using AMG 900, a small molecule pan aurora kinase inhibitor, for the treatment of cancer, including solid tumors, hematologically derived tumors and the like. The invention further provides pharmaceutical compositions, dosage ranges and treatment regimens for administering AMG 900 to treat cancer. | 12-05-2013 |
20130323199 | COLLAGEN MATERIAL AND METHOD FOR PRODUCING COLLAGEN MATERIAL - A collagen material is characterized in being constituted of collagen gel fragments. Furthermore, the collagen gel fragments may have an orientation. A method for producing a collagen material is characterized in comprising a step for preparing collagen gel fragments, a step for arranging the collagen gel fragments in a desired shape, and a step for drying the collagen gel fragments arranged in the desired shape. Moreover, in one embodiment of the method for producing a collagen material a step may include imparting an orientation to the collagen gel fragments. | 12-05-2013 |
20130336922 | HLA-BINDING PEPTIDES DERIVED FROM PROSTATE-ASSOCIATED ANTIGENIC MOLECULES AND METHODS OF USE THEREOF - Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. More specifically methods of treating patients with prostate cancer comprising administering compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants, are disclosed. | 12-19-2013 |
20130344025 | METHOD FOR THE ADMINISTRATION OF LIGANDS, AGONISTS OF LIGANDS OF THE TNF FAMILY WITH REDUCED TOXICITY - The present invention concerns the use of a multimerized form of ligands of the TNF family for the preparation of a medicament for injection into an appropriate cavity of the body, for the treatment of diseases wherein cell proliferation has to be controlled wherein the ligand of the TNF family is selected among Fas ligand, CD40L, TRAIL and APRIL. | 12-26-2013 |
20130344026 | Dimeric Smac Mimetics - The invention provides small molecule mimics of the Smac peptide that are dimers or dimer-like compounds having two binding domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders. | 12-26-2013 |
20140004076 | RECOMBINANT HUMAN G-CSF DIMER AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES | 01-02-2014 |
20140010777 | METHODS FOR DETERMINING PERSONALIZED TREATMENT COMPOSITIONS FOR PROSTATE CANCER AND BREAST CANCER - The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a cancer, such as prostate or breast cancer, in a patient wherein the treatment composition includes administering a combination of at least two components selected from two different classes of compounds. Methods for treating a patient using the selected treatment composition are also provided, together with methods for monitoring the efficacy of the treatment composition during a treatment period. | 01-09-2014 |
20140017193 | Methods for treating nervous system injury and disease - The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents. | 01-16-2014 |
20140023612 | Granulocyte-Macrophage Colony Stimulating Factor for Enhancing Pulmonary Host Defense in Acute and Chronic Radiation Syndrome, Therapeutic Radiation Intervention and Cancer Therapy - Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and/or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided. | 01-23-2014 |
20140030211 | METHODS FOR OBTAINING A THERAPEUTICALLY EFFECTIVE AMOUNT OF HEMATOPOIETIC PRECURSOR CELLS AND LONG TERM ENGRAFTMENT THEREOF - The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved. | 01-30-2014 |
20140030212 | COMPOSITIONS, METHODS AND DEVICES FOR ACTIVATING AN IMMUNE RESPONSE - The invention provides a method, system, process, vaccine, or device for activating an immune response against a tumor. In particular, in one embodiment, the invention for activating an immune response in situ against a tumor comprises introducing one or more delivery devices having a morphology that prioritizes one or more prioritized cell types which interface with the one or more delivery devices. In another embodiment, the invention provides a method of vaccinating to activate the innate immune system of a subject which comprises administering a vaccine comprising a composition selected from a group consisting of: a selection factor, an antigenic target, an immunogenic enchancing factor, and combinations thereof. | 01-30-2014 |
20140030213 | Process for Purification of Recombinant Granulocyte Colony Stimulating Factor (RHU GCSF) - The present invention relates to methods for purification of recombinant human granulocyte colony stimulating factor (rHu GCSF). The present invention particularly relates to methods for purification of rHu GCSF involving techniques such as aqueous two phase extraction and multimodal chromatographic purification to obtain highly purified rHu GCSF. The present invention also provides a pharmaceutical composition comprising the rHu GCSF, purified using the methods described herein. | 01-30-2014 |
20140030214 | LIQUID FORMULATION OF G-CSF - Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits. | 01-30-2014 |
20140030215 | Macrophage Activating Factor For Pharmaceutical Compositions - Pharmaceutical compositions including macrophage activating factor (MAF) and method of producing same, particularly to MAF compositions essentially devoid of glycosidase enzymes. The compositions of the present invention and pharmaceutical compositions including same are particularly suitable for intravenous administration. | 01-30-2014 |
20140037576 | P2X7: Inhibition Of Epithelial Cancers and Papillomas - The present invention demonstrates that P2X | 02-06-2014 |
20140037577 | ANTI-PARASITIC METHODS AND COMPOSITIONS UTILIZING DIINDOLYLMETHANE-RELATED INDOLES - The present invention includes methods and compositions for the treatment and prevention of protozoal parasitic infections utilizing Diindolylmethane-related indoles. Additive and synergistic interaction of Diindolylmethane-related indoles with other known anti-parasitic and pro-apoptotic agents is believed to permit more effective therapy and prevention of protozoal parasitic infections. The methods and compositions described provide new treatment of protozoal parasitic diseases of mammals and birds including malaria, leishmaniasis, trypanosomiasis, trichomoniasis, neosporosis and coccidiosis. | 02-06-2014 |
20140044672 | CONJUGATES OF A GM-CSF MOIETY AND A POLYMER - Conjugates of a GM-CSF moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions comprising conjugates to a patient. | 02-13-2014 |
20140056842 | CELLULAR THERAPEUTIC APPROACHES TO TRAUMATIC BRAIN AND SPINAL CORD INJURY - The described invention provides cellular therapeutic approaches for treating a vascular insufficiency following a traumatic injury to head or spine that results in an injury to brain, spinal cord, or both by administering a therapeutic amount of an isolated, nonexpanded population of autologous mononuclear cells comprising a subpopulation of CD34+ cells, which further contains a subpopulation of potent SDF-1 mobile CD34+/CXCR-4 cells that have CXCR-4-mediated chemotactic activity. | 02-27-2014 |
20140056843 | TNFSF SINGLE CHAIN MOLECULES - The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications. | 02-27-2014 |
20140086867 | Systems, Compositions and Methods for the Treatment of Alopecia - A method of inducing or promoting hair growth on the scalp of a subject, comprising the steps of (i) providing an ECM composition including at least one ECM material, (ii) administering inciting event means to a target location on the scalp of the subject to induce an inciting event at the target scalp location, and (iii) administering a therapeutically effective amount of said ECM composition to the target scalp location. In some embodiments, the ECM composition includes at least one additional biologically active agent. | 03-27-2014 |
20140093475 | Suppression of Bone Loss by Introducing FoxP3+ CD8 T-cells (TcREG) - Systems and methods for inhibiting bone loss using FoxP3+ CD8 T-cells (Tc | 04-03-2014 |
20140099279 | METAL ALLOYS FOR MEDICAL DEVICES - A medical device that is at least partially formed of a novel metal alloy, which novel metal alloy improves the physical properties of the medical device. | 04-10-2014 |
20140105853 | PROSTATE CANCER VACCINE - Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines. | 04-17-2014 |
20140127155 | Smac mimetic dimers and trimers useful as anti-cancer agents - The invention provides small molecule mimics of the Smac peptide that are dimer-like or trimer-like compounds having two or three amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders. | 05-08-2014 |
20140154205 | ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR THERAPEUTIC AND COSMETIC APPLICATIONS - A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm | 06-05-2014 |
20140161765 | DERIVATISATION OF GRANULOCYTE COLONY-STIMULATING FACTOR - The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds. | 06-12-2014 |
20140170107 | REGULATION OF ENERGY METABOLISM AND OBESITY BY MODULATING B CELL ACTIVATING FACTOR (BAFF, BLYS) OR BAFF SIGNALING - Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors. | 06-19-2014 |
20140178329 | VARIANTS OF THE TNF SUPERFAMILY AND USES THEREOF - Described are novel variants of APRIL that modulate signaling via receptor-specific agonist activity, and nucleic acids encoding these variant proteins. Further described is the use of these novel proteins in the treatment of APRIL-associated disorders, in particular, pathologies of the immune system and oncological disorders. | 06-26-2014 |
20140186292 | DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE - Methods are disclosed for producing defective ribosomal products (DRiPs) in blebs (DRibbles) by contacting cells with a proteasome inhibitor, and in some examples also an autophagy inducer, thereby producing treated cells. DRibbles can be used to load antigen presenting cells (APCs), thereby allowing the APCs to present the DRiPs and antigenic fragments thereof. Immunogenic compositions that include treated cells, isolated DRibbles, or DRibble-loaded APCs are also disclosed. Methods are also provided for using treated cells, isolated DRibbles, or DRibble-loaded APCs to stimulate an immune response, for example in a subject. For example, DRibbles obtained from a tumor cell can be used to stimulate an immune response against the same type of tumor cells in the subject. In another example, DRibbles obtained from a pathogen-infected cell or cell engineered to express one or more antigens of a pathogen can be used to stimulate an immune response against the pathogen in the subject. | 07-03-2014 |
20140193357 | DERIVATIVES OF RECOMBINANT PROTEINS, HOMO-MULTIMERS OF GRANULOCYTE COLONY-STIMULATING FACTOR AND METHOD OF PREPARATION THEREOF - The invention relates to derivatives of recombinant proteins, comprising homo-multimers of genetically fused recombinant biologically active protein monomer units, connected via selected peptide linker moiety; and the method of preparation thereof. Derivative of recombinant protein is preferably dimer of human granulocyte colony-stimulating factor, characterised by increased circulation time in vivo. | 07-10-2014 |
20140199258 | LISTERIA-BASED ADJUVANTS - This invention provides methods and compositions for using | 07-17-2014 |
20140219952 | METHODS OF TREATMENT USING STEM CELL MOBILIZERS - The present invention relates to the field of stem cells. In one aspect, the present invention provides methods of treating a subject with acute liver injury comprising administering to the subject a therapeutically effective amount of at least one stem cell mobilizer. In particular embodiments, the subject is treated with plerixafor and G-CSF | 08-07-2014 |
20140219953 | ADHESIVE CELL TISSUE GELS - Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent. | 08-07-2014 |
20140219954 | DRY POWDER FORMULATIONS OF ORGANIC MACROMOLECULES - The present invention relates to methods for making a stabilized powder formulation for inhalation comprising a macromolecule in lyophilized form, a crystalline carrier material, and magnesium stearate. | 08-07-2014 |
20140248234 | USE OF G-CSF DIMER IN PREPARATION OF MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES - The invention discloses the use of the G-CSF dimer in the preparation of a medicament for the treatment of neurodegenerative diseases. Use of the G-CSF dimer of the present invention can significantly increase the number of dopaminergic neuron in the substantia nigra in PD model animals and enhance the function of dopaminergic neurons. In addition, the G-CSF dimer can significantly reduce apoptosis of neuron in hippocampus and improve learning and memory ability of AD model rats. Serum half-life of the G-CSF dimer of the invention is prolonged and the loss of neurons is effectively prevented, providing a better therapeutic effect in treatment of neurodegenerative disease. | 09-04-2014 |
20140255337 | METHODS OF TREATING COGNITIVE IMPAIRMENT - The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment. | 09-11-2014 |
20140255338 | EDAR LIGAND DERIVED PEPTIDES AND USE THEREOF - The present invention relates to novel peptides derived from an EDAR (EDAR receptor) ligand which belongs to TNF (tumor necrosis factor)-α family and to uses of the same. The present peptides of EDA3 derived from EDA and EDphD1 derived from EDAR ligand possess identical or similar activities to naturally occurring EDA and have much higher stability and skin penetration potency than naturally occurring EDA. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss and promotion of hair growth, but also has superior efficacies on treatment of an EDA signal transduction pathway-related disorder. In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics. | 09-11-2014 |
20140271538 | Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients - Disclosed are methods and compositions for treating, preventing and ameliorating conditions and diseases characterized by a lowered white blood cell count, including neutropenia, in human patients that are less than 18 years old. The methods and compositions described herein include a fusion polypeptide comprising human serum albumin protein (“HSA”) and human granulocyte-colony stimulating factor (“G-CSF”). | 09-18-2014 |
20140286895 | Methods and Compositions for Promoting Organ Development - Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or fetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof, or otherwise, at least one nucleic acid molecule encoding colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof. | 09-25-2014 |
20140294753 | NOVEL USE OF GANODERMIC ACIDS FOR TREATING CANCER - Novel Uses of a small molecule, ganodermic acid S (GMAS), are disclosed herein. The GMAS is useful as a lead compound for manufacturing a medicament or a pharmaceutical composition for treating cancer, including metastatic or drug-resistant cancer, in a patient. | 10-02-2014 |
20140294754 | USE OF TUMOR FAS EXPRESSION TO DETERMINE RESPONSE TO ANTI-CANCER THERAPY - The invention provides methods for using expression levels of Fas to select individuals or subpopulation of individuals who can benefit from an anti-cancer therapy and for assessing whether an individual suspected of having or developing cancerous tumors will beneficially respond to an anticancer therapy. The invention additionally provides methods of treatment for individuals selected as likely to benefit from anti-cancer therapy based on Fas expression levels. | 10-02-2014 |
20140294755 | Materials and Methods Relating to Stem Cell Mobilization by Multi-Pegylated Granulocyte Colony Stimulating Factor - The present invention relates to the use of multi-PEGylated granulocyte colony stimulating factor (G-CSF) preparations to mobilize hematopoietic stem cells. | 10-02-2014 |
20140294756 | Long-Term Storage of Non-Glycosylated Recombinant Human G-CSF - The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing the non-glycosylated recombinant human G-CSF and sorbital is cooled to a temperature of −15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state and then increased in temperature to a temperature within the range of from 2° C. to 8° C. for a period of time adjusted to allow the composition to thaw and to obtain a liquid composition having a G-CSF content of at least 95% of the G-CSF content of the original composition. | 10-02-2014 |
20140294757 | STABILISATION OF POLYPEPTIDES - A method for preserving a polypeptide comprising: (a) providing an aqueous solution of (i) the polypeptide, (ii) one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating the polypeptide. | 10-02-2014 |
20140301973 | COMBINATION THERAPIES FOR TREATING TYPE 1 DIABETES - In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes. | 10-09-2014 |
20140314708 | DUAL DELIVERY SYSTEM FOR HETEROLOGOUS ANTIGENS - Provided herein are recombinant | 10-23-2014 |
20140322160 | METHOD AND COMPOSITION FOR ALTERING A B CELL MEDIATED PATHOLOGY - The present invention provides compositions for altering a B cell mediated pathology in a patient. The compositions may comprise at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the VH or VL region of an immunoglobulin module from particular B cells from a patient having a B cell mediated pathology, and an immunoglobulin constant region. The genes encoding VH and/or VL regions and the genes encoding immunoglobulin constant regions are isolated and inserted in an expression vector. The chimeric proteins may be produced by introducing the expression vectors into insect cell lines. Proteins may be further purified and conjugated to a compound such as a immunogenic carrier. | 10-30-2014 |
20140335046 | Compositions, Methods and Systems for Regenerative Cosmetics - A method of inducing or promoting hair growth on the scalp of a subject, comprising the steps of (i) providing an ECM composition including at least one ECM material, (ii) administering inciting event means to a target skin location on the subject to induce an inciting event, and (iii) administering a therapeutically effective amount of said ECM composition to the target skin location. In some embodiments, the ECM composition includes at least one additional biologically active agent. | 11-13-2014 |
20140341841 | MIRNA biomarkers for radiation biodosimetry - Disclosed herein are miRNA biomarkers and methods for measuring exposure of a mammalian subject to ionizing radiation using a cell-free biological sample. Also disclosed are dosimeters and methods for triaging and treating a subject exposed to ionizing radiation. | 11-20-2014 |
20140341842 | THIOLATED HYALURONAN-BASED HYDROGELS CROSS-LINKED USING OXIDIZED GLUTATHIONE - The invention provides methods, compositions and kits relating to hyaluronan based matrices using oxidized glutathione as a crosslinking agent. | 11-20-2014 |
20140377214 | MATERIALS AND METHODS TO ENHANCE HEMATOPOIETIC STEM CELLS ENGRAFTMENT PROCEDURES - This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE | 12-25-2014 |
20140377215 | DELIVERY OF THERAPEUTIC AGENTS BY A COLLAGEN BINDING PROTEIN - Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided. | 12-25-2014 |
20140377216 | ANTICANCER FUSION PROTEIN - A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino acid hTRAIL281; and at least one domain (b) which is a sequence of a cytolytic effector peptide forming pores in the cell membrane, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases. | 12-25-2014 |
20150010494 | POLYSACCHARIDE-PROTEIN CONJUGATES REVERSIBLY COUPLED VIA IMINE BONDS - A method of preparing an oxidised polysaccharide-protein conjugate by oxidising a polysaccharide with an oxidising agent to form an oxidised polysaccharide and combining such oxidised polysaccharide with a protein. The oxidised polysaccharide is reacted with a protein to form a composition comprising a conjugate wherein the oxidised polysaccharide and the protein are conjugated via one or more imine bonds and wherein the oxidised polysaccharide comprises essentially no alpha-hydroxy aldehyde units. The conjugate may be used to provide sustained or latent activity of the protein. | 01-08-2015 |
20150017119 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN. | 01-15-2015 |
20150023907 | REACTIVATION OF HIV-1 GENE EXPRESSION TO TREAT PERSISTENT HIV INFECTION - The present invention provides new methods of treatment of lentiviral infections, more particularly to treat latent retroviral HIV infections, present in cells of the infected subject, based on the re-activation of said viruses. The invention uses a combination therapy using several agents that result in strong re-activation of the latent HIV-virus that could destroy the infected cells and elicite an immune response in the subject. This could present further spread of the infection, with the ultimate aim to eradicate the virus completely in said subject. | 01-22-2015 |
20150030561 | Use of CXCR4 Antagonists - Presently disclosed are methods and compositions for treating or preventing WHIM syndrome and certain other disorders or conditions with a certain CXCR4 antagonist. | 01-29-2015 |
20150044162 | ANTICANCER FUSION PROTEIN - A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino acid hTRAIL281; and domain (b) which is a sequence of an effector peptide inhibiting protein synthesis, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases. | 02-12-2015 |
20150044163 | A Method for Cuticle Growth using Granulocyte-Colony Stimulating Factor - The present invention provides a method for re-growing hair in patients with androgenic alopecia by administering effective consecutive courses of Granulocyte-Colony Stimulating Factor or derivatives. After the state of re-growth is obtained, the hair growth is maintained by administering periodic courses of Granulocyte-Colony Stimulating Factor or derivatives. The invention further provides a method for increasing cuticle growth and density using a similar administration of effective consecutive courses of Granulocyte-Colony Stimulating Factor or derivatives. The increased cuticle growth and density is maintained by administering periodic courses of Granulocyte-Colony Stimulating Factor or derivatives. | 02-12-2015 |
20150056159 | The IgM and IgE Heavy Chain Domain 2 as Covalently Linked Homodimerization Modules for the Generation of Fusion Proteins with Dual Specificity - The present invention provides a polypeptides comprising a heavy chain domain 2 (HD2) from IgM or IgE and at least one pharmaceutically active moiety, complexes thereof and their use for therapy and prophylaxis. | 02-26-2015 |
20150064132 | Treatment Methods for Rheumatoid Arthritis - The present invention provides methods for selecting treatment methods for rheumatoid arthritis based on an objective selection process (algorithm). The present invention also provides methods for treating rheumatoid arthritis with treatment methods selected based on the algorithm disclosed herein. The methods of the present invention provide a more effective means for treating patients with rheumatoid arthritis. | 03-05-2015 |
20150071873 | Cancer Treatment by Immunotherapy With BCG or Antigenically Related Non-Pathogenic Mycobacteria - A first and a second identical or different mycobacterial immunogenic compositions, each comprising at least a | 03-12-2015 |
20150079022 | USE OF AMG 900 FOR THE TREATMENT OF CANCER - The present invention relates to methods of using AMG 900, a small molecule pan aurora kinase inhibitor, for the treatment of cancer, including solid tumors, hematologically derived tumors and the like. The invention further provides pharmaceutical compositions, dosage ranges and treatment regimens for administering AMG 900 to treat cancer. | 03-19-2015 |
20150098924 | METHOD FOR EX-VIVO PURGING IN AUTOLOGOUS TRANSPLANTATION - The present invention concerns a new method for ex-vivo purging of cells in autologous transplantation, wherein the sample of taken cells is treated with a sufficient amount of a multimeric form of the soluble portion of FasL to kill malignant cells without substantially affecting viability of cells to be transplanted. Autologous stem cell transplantation (ASCT) following high-dose chemotherapy with or without radiotherapy has become the standard therapy for the majority of patients with large-cell lymphomas, multiple myeloma, and refractory/recidivating Hodgkin's disease. Such therapy is nowadays also contemplated for selected patients with low-grade lymphomas (chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma) and for patients with acute myeloid leukemia (AML). Current treatments for cell purging include chemotherapy and antibody cocktails. These treatments are often toxic on stem cells and not efficient in eliminating cancer cells. Thus, there is an unmet medical need for cell purging in ASCT which this project will address. | 04-09-2015 |
20150104409 | HUMAN MONOCLONAL ANTIBODIES TO CTLA-4 - In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein. | 04-16-2015 |
20150104410 | SERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF - This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules. | 04-16-2015 |
20150104411 | NOVEL ANTITUMORAL USE OF CABAZITAXEL - The invention relates to a compound of formula: | 04-16-2015 |
20150104412 | Materials and Methods Useful for Affecting Tumor Cell Growth, Migration and Invasion - It is disclosed herein that miR-221 and miR-222 down-regulate PTEN and TIMP3 tumor suppressors, resulting in TRAIL resistance. The present invention provides research, diagnostic, and therapeutic tools and methods related to this discovery. Diagnostics, prognostics and treatments for human hepatocellular cancer and non-small cell lung carcinoma having a TRAIL resistance are particularly described herein. | 04-16-2015 |
20150110734 | TRAIL SINGLE CHAIN MOLECULES - The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications. | 04-23-2015 |
20150118181 | Concurrent Chemotherapy and Immunotherapy - The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy. In fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine. | 04-30-2015 |
20150118182 | NOVEL ANTITUMORAL USE OF CABAZITAXEL - The invention relates to a compound of formula: | 04-30-2015 |
20150125419 | TRAIL SINGLE CHAIN MOLECULES - The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications. | 05-07-2015 |
20150125420 | LIQUID FORMULATION OF G-CSF - Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits. | 05-07-2015 |
20150139936 | DOSAGE AND ADMINISTRATION OF BISPECIFIC SCFV CONJUGATES IN COMBINATION WITH ANTI-CANCER THERAPEUTICS - Provided are methods and compositions for clinical treatment of advanced HER2 positive solid tumors cancer using combination therapies comprising bispecific anti-ErbB2/anti-ErbB3 antibodies. | 05-21-2015 |
20150139937 | Methods and Compositions For Inhibiting Diseases of the Central Nervous System - Methods and compositions for treating central nervous system diseases and disorders are disclosed. | 05-21-2015 |
20150139938 | Methods and Compositions for Improving Pial Collateral Circulation and Treating Blood Clotting Disorders - The present invention provides methods of promoting arteriogenesis in a subject. Embodiments include methods comprising: administering an effective dose of tocotrienol to the subject; causing an increase in Tissue Inhibitor of Metalloproteinase Metallopeptidase Inhibitor 1 (TIMP1) in vessels of cerebrovascular collateral circulation in the subject; attenuating the activity of Matrix Metalloproteinase-2 (MMP2); thereby promoting arteriogenesis. | 05-21-2015 |
20150147290 | USE OF G-CSF DIMER IN THE TREATMENT OF NEUTROPENIA - This invention relates to a use of G-CSF dimer in the treatment of neutropenia. In particular, the recombinant human G-CSF of the present invention can enhance the differentiation and development of neutrophils in animal, and thus effectively reduce the severity of the severe neutropenia and shorten the time of severe neutropenia for the post-chemotherapy cancer patients. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased, providing a better effect in the treatment of neutropenia. | 05-28-2015 |
20150147291 | Zinc Chelating Agents for Depleting Xiap and Sensitizing Tumor Cells to Apoptosis - The invention provides zinc chelating agents and formulations thereof that deplete XIAP in cancer cells and sensitize the cells to apoptosis-inducing agents. The invention provides methods for sensitizing apoptosis-resistant cancer cells to apoptosis-inducing agents, as well as methods for treating a subject with a combined therapy of a zinc chelating agent and an apoptosis-inducing agent. | 05-28-2015 |
20150291594 | Deuterated Ponatinib - The present invention provides novel derivatives of ponatinib (AP-24534), a BCR-ABL kinase inhibitor with activity against the T3151 Gatekeeper mutant. | 10-15-2015 |
20150291636 | ANTIBACTERIAL COMPOUNDS AND BIOLOGICAL APPLICATIONS THEREOF - The invention relates to compounds of formulae (Ia), (Ib) or (Ic) wherein, A | 10-15-2015 |
20150293113 | SEROLOGICAL MARKERS OF INFLAMMATORY BOWEL DISEASE PHENOTYPE AND DISEASE PROGRESSION - Disclosed are novel biomarkers and methods related to diagnostic tests for the detection and characterization of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. In particular, the instant invention relates to novel biomarkers and methods of using such biomarkers to predict disease behavior and severity, to differentiate among disease types, and to optimize selection of treatment options in individuals suspected of having an inflammatory bowel disease | 10-15-2015 |
20150297553 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL - The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol. | 10-22-2015 |
20150297576 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - The invention relates to compositions comprising an acid ceramidase inhibitor and a choline kinase inhibitor as well as to the uses thereof for the treatment of cancer. The invention also relates to methods for the selection of an individualised therapy of a cancer patient based on the detection of the acid ceramidase levels. Moreover, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent and uses thereof for the treatment of cancer. Finally, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent or a death receptor ligand and uses thereof for the treatment of cancer. | 10-22-2015 |
20150297695 | XBP1, CD138, AND CS1 PEPTIDES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE PEPTIDES, AND METHODS OF USING SUCH PEPTIDES AND COMPOSITIONS - The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells. | 10-22-2015 |
20150306180 | GM-CSF FOR USE IN THE PREVENTION OF SPONTANEOUS ABORTION AND EMBRYO IMPLANTATION FAILURE - The invention relates to GM-CSF for use in a method for the prevention of spontaneous abortion in a subject suffering from recurrent miscarriage, comprising administering to said subject an effective amount of GM-CSF as sole active substance, wherein said method also prevents or reduces the likelihood of embryo implantation failure in the subject undergoing an assisted reproduction procedure. | 10-29-2015 |
20150306197 | PROSTATE CANCER VACCINE - Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines. | 10-29-2015 |
20150314012 | Protein Conjugates - The present invention concerns the field of conjugated peptides suitable for the production of drugs having an improved plasma half-life. In particular the present invention relates to a conjugated protein, obtained by an enzymatic reaction via microbial transglutaminase (MTGase), and an improved process for removing residual transglutaminase from peptides or recombinant proteins enzymatically conjugated by microbial transglutaminase (MTGase) to hydrophilic non-immunogenic polymer at a glutamine side-chain through an amidic linkage, allowing to obtain purified conjugated peptides or proteins which are stable against the enzymatic hydrolysis of the amidic bond between the peptide or protein moiety and the hydrophilic polymer and being free from product derived degradation displays the stability required for a drug. | 11-05-2015 |
20150328286 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF SPONTANEOUS ABORTION IN A HUMAN FEMALE - Methods and kits for preventing or reducing the likelihood of implantation failure or miscarriage in a recipient of artificial insemination are provided. The methods include administering into a recipient of artificial insemination in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF). | 11-19-2015 |
20150328297 | TARGET PEPTIDES FOR COLORECTAL CANCER THERAPY AND DIAGNOSTICS - A set of target peptides are presented by HLA A*0201, B*0301, B*0702 and B*2705 on the surface of disease cells. They are envisioned to, among other things, stimulate an immune response to the proliferative disease, e.g., colorectal cancer, to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, facilitate antibody recognition of tumor boundaries in surgical pathology samples, act as biomarkers for early detection and/or diagnosis of the disease, and/or act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex. | 11-19-2015 |
20150337023 | Colon and Pancreas Cancer Peptidomimetics - The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods. | 11-26-2015 |
20150343077 | Anti-CD37 Immunoconjugate Dosing Regimens - Methods of administering immunoconjugates that bind to CD37 are provided. The methods comprise administering an anti-CD37 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects. | 12-03-2015 |
20150352103 | USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF AUTOIMMUNE DISORDERS - The embodiments described herein include methods and formulations for treating autoimmune disorders. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. | 12-10-2015 |
20150361396 | T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF - This invention relates generally to compositions and methods for identifying the regulatory network that modulates, controls or otherwise influences T cell balance, for example, Th17 cell differentiation, maintenance and/or function, as well compositions and methods for exploiting the regulatory network that modulates, controls or otherwise influences T cell balance in a variety of therapeutic and/or diagnostic indications. This invention also relates generally to identifying and exploiting target genes and/or target gene products that modulate, control or otherwise influence T cell balance in a variety of therapeutic and/or diagnostic indications. | 12-17-2015 |
20150366844 | COMPOSITION COMPRISING A TNFR AGONIST AND AT LEAST ONE THIOREDOXIN INHIBITOR FOR USE IN THE TREATMENT OF CARCINOMA - A composition for the treatment of cancerous cells. The composition including a combination of at least one tumor necrosis factor receptor (TNFR) agonist and at least one thioredoxin inhibitor. This combinatorial approach involves direct inhibition of the thioredoxin molecule (and not the enzyme of Trx reductase). | 12-24-2015 |
20150366943 | MOBILIZATION OF HEMATOPOIETIC STEM CELLS FROM BONE MARROW TO BLOOD USING A COMBINATION OF A ROBO4 RECEPTOR ANTAGONIST AND A CXCR4 ANTAGONIST OR hrVEGF-165 AND A CXCR4 ANTAGONIST - The invention herein disclosed provides for compositions, methods for synthesizing said compositions, and methods for using said compositions, wherein the compositions and methods may be used in clinical treatment using hematopoietic transplantation, particularly to those relating to treatment of cancer and metastasis. The compositions regulate mobilization of hematopoietic stem cells (HSCs) between bone marrow (BM) and the peripheral blood (PB). | 12-24-2015 |
20150374582 | DELAMINATION RESISTANT PHARMACEUTICAL GLASS CONTAINERS CONTAINING ACTIVE PHARMACEUTICAL INGREDIENTS - The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, NEUPOGEN (filgrastim), NEULASTA (pegfilgrastim), EPOGEN (epoetin alfa) or ENBREL (etanercept). | 12-31-2015 |
20150374736 | URIDINE DIPHOSPHATE COMPOUNDS AS MOBILIZERS OF HEMATOPOIETIC PROGENITOR CELLS - The present invention provides for compositions and methods for administering one or more UDP compound, alone or in combination with another hematopoietic progenitor cell mobillizing compound (for example, but not limited to G-CSF), to mobilize hematopoietic progenitor cells for transplant or other purposes. The methods of the invention may be particularly advantageous as applied to improve the stem cell yield in so-called “poor mobilizing” patients. | 12-31-2015 |
20160002325 | ANTI-CXCL13 ANTIBODIES AND ASSOCIATED EPITOPE SEQUENCES - The invention relates to epitopes of CXCL13 and to binding agents, such as antibodies, that specifically bind to CXCL13. | 01-07-2016 |
20160008434 | STEM CELL FOR THERAPEUTIC USE WHICH IS DERIVED FROM HUMAN MONOCYTE, AND METHOD FOR INDUCING SAME | 01-14-2016 |
20160015745 | Formulations of Antimicrobial, Antiviral, and Antineoplastic Compounds In Combination With Certain Wavelengths of Light - Formulations of antimicrobial, antiviral, and antineoplastic compounds in combination with certain wavelengths of light include a solution that includes an oxidizer; the solution having an initial therapeutic effectiveness; and a light of a predetermined frequency that that undergoes a synergistic reaction with the oxidizer, thereby enhancing the initial therapeutic effectiveness of the solution. A method of drug-enhancement includes providing a drug that includes hydrogen peroxide and a therapeutic chemical, the drug having an initial therapeutic effectiveness; and applying light having a predetermined frequency of light that has a synergistic reaction with the drug, thereby enhancing the initial therapeutic effectiveness of the drug. | 01-21-2016 |
20160015786 | MOBILIZING AGENTS AND USES THEREFOR - Disclosed is the use of a HIF-α potentiating agent and a mobilizer of hematopoietic stem cells and/or progenitor cells in methods and compositions for mobilizing hematopoietic stem cell and progenitor cells from the bone marrow into the peripheral blood. The compositions and methods are particularly useful for stem cell transplantation and for treating or preventing immune deficiencies. | 01-21-2016 |
20160017293 | INDIVIDUALIZED HIGH PURITY HEPATOCELLULAR CARCINOMA STEM CELLS, METHODS AND USE OF THE SAME - The disclosure provides cancer stem cells, for use in stimulating immune response against a cancer, such as hepatocellular carcinoma (HCC). Methods for preparing and purifying the cancer stem cells are provided. | 01-21-2016 |
20160022790 | VACCINE FOR THE PREVENTION OF BREAST CANCER RECURRENCE - Provided are methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, GP2, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission, including patients having low to intermediate levels of HER2/neu expression. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as GM-CSF, and the GP2 peptide. The methods may further comprise administering a periodic booster vaccine dose as needed due to declining GP2-specific T cell immunity. Also provided are vaccine compositions for use in the methods. | 01-28-2016 |
20160024220 | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CD6 MONOCLONAL ANTIBODY USED IN THE DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS - The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-CD6 monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis. | 01-28-2016 |
20160030535 | Method of Induction and Purification of a Cell Population Responsible for Vascular Mimicry and Use of Same - The disclosure provides cancer stem cells responsible for vascular mimicry, for use in stimulating immune response against a cancer. Methods for preparing and purifying the cancer stem cells are provided. | 02-04-2016 |
20160030537 | Individualized High Purity Glioblastoma Multiforme Stem Cells and Methods for Stimulating Immune Response - The present disclosure provides reagents and methods for stimulating an immune response against an antigen associated with glioblastoma multiforme. | 02-04-2016 |
20160040126 | REGULATION OF DIFFERENTIATION INTO DOPAMINERGIC NEURONS BY METALLOPROTEASE - The present invention relates to a method for regulating the differentiation of neural stem cells or neural progenitor cells into dopaminergic neural cells, the method comprising increasing or inhibiting the activity of ADAM17 and/or ADAM10 in neural stem cells or neural progenitor cells, and to the use of an activator or inhibitor of ADMA17 and/or ADAM10. | 02-11-2016 |
20160051653 | TUMOR VACCINATION IN COMBINATION WITH HEMATOPOIETIC CELL TRANSPLANTATION FOR CANCER THERAPY - In one aspect, the present invention provides a method for treating cancer comprising tumor cell vaccination in combination with hematopoietic and immune cell transplantation. In some embodiments, the method involves autologous tumor cell vaccination prior to autologous hematopoietic and immune cell transplantation. In another aspect, the present invention provides a method of purifying tumor cells from a subject in preparation for vaccination. | 02-25-2016 |
20160058810 | COMPOSITION CONTAINING ANGELICA EXTRACT FOR PROMOTING PROLIFERATION OF STEM CELLS DERIVED FROM BONE MARROW - The present invention relates to a composition for promoting proliferation of bone marrow derived stem cells using an angelicae gigantis radix extract, and more particularly, to a composition which administers a granulocyte colony-stimulating factor into an object, and administers the angelicae gigantis radix extract to the object to promote the proliferation of the bone marrow derived stem cells. The composition of the present invention solves side effects such as splenomegaly which were caused by a method of administering only the G-CSF for proliferation and differentiation of the stem cells, thereby significantly mitigating the side effects through co-administration of the angelicae gigantis radix extract, and further promoting the proliferation and the differentiation of the stem cells. | 03-03-2016 |
20160058855 | HIGH PURITY OVARIAN CANCER STEM CELLS FOR ACTIVE AUTOLOGOUS IMMUNE THERAPY - The disclosure provides cancer stem cells, for use in stimulating immune response against a cancer, such as ovarian carcinoma. Methods for preparing and purifying the cancer stem cells are provided. | 03-03-2016 |
20160074489 | STIMULATION OF IMMUNITY TO TUMOR SPECIFIC AND ENDOTHELIAL SPECIFIC PROTEINS BY IN VIVO DC ATTRACTION AND MATURATION - Treatment of cancer is disclosed through administration of proteins or specific peptides in vivo, in a matter eliciting monocyte or dendritic cell migration in order to allow uptake of said administrated proteins or peptides, followed by administration of a maturation signal in vivo. The invention provides for treatment of cancer through induction of anticancer immunity and/or immunity towards tumor associated blood vessels. | 03-17-2016 |
20160075750 | Production of TSG-6 Protein - A method of producing a protein or polypeptide, such as, for example, TSG-6 protein, or a biologically active fragment, derivative or analogue thereof, by introducing into mammalian cells a polynucleotide encoding the biologically active protein or polypeptide or biologically active fragment, derivative, or analogue thereof. The cells then are suspended in a protein-free medium that includes at least one agent that suppresses production of hyaluronic acid, hyaluronan, or a salt thereof by the cells. The cells are cultured for a time sufficient to express the biologically active protein or polypeptide or biologically active fragment, derivative or analogue thereof. The biologically active protein or polypeptide, or fragment, derivative, or analogue thereof then is recovered from the cells, such as, for example, by recovering the protein or polypeptide secreted by the cells from the cell culture medium. | 03-17-2016 |
20160077096 | TREATING PATIENTS BASED ON IMMUNE SUBTYPES - This document provides methods and materials for treating patients following an assessment of immune subtypes such as an assessment of peripheral blood phenotypes. For example, methods and materials for treating a mammal having a medical condition after assessing a mammal's level of CD14+/DR− cells (e.g., CD14+/DR− monocytes) and level of CD4+ cells (e.g., CD4+ T cells) and classifying the mammal has being likely to experience a favorable or unfavorable medical outcome based at least in part on the mammal's level of CD14+/DR− cells and level of CD4+ cells are provided. | 03-17-2016 |
20160082092 | APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES - The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer. | 03-24-2016 |
20160089424 | APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES - The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer. | 03-31-2016 |
20160089425 | APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES - The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer. | 03-31-2016 |
20160089426 | APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES - The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer. | 03-31-2016 |
20160090403 | VIRUS LIKE PARTICLE COMPOSITION - The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof. | 03-31-2016 |
20160095911 | APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES - The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer. | 04-07-2016 |
20160095912 | APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES - The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer. | 04-07-2016 |
20160095930 | Derivatisation of Granulocyte Colony-Stimulating Factor - The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds. | 04-07-2016 |
20160101155 | METHODS OF TREATING NEUROLOGICAL AUTOIMMUNE DISORDERS WITH CYCLOPHOSPHAMIDE - Described herein are methods for treating neurological autoimmune disorders in which the treatment method includes administering an immunoablative agent to eliminate most or essentially all maturing and mature elements of the immune system in an affected individual. Following this step, the individual is administered agents to reestablish the ablated immune system. | 04-14-2016 |
20160101156 | COMPOSITION CONTAINING PALMULTANG EXTRACT FOR PROMOTING PROLIFERATION OF STEM CELLS DERIVED FROM BONE MARROW - The present invention relates to a composition for promoting the proliferation of stem cells derived from bone marrow using a palmultang extract, and more specifically, to a composition for promoting the proliferation of stern cells derived from bone marrow by administering a granulocyte colony-stimulating factor to a subject and then administering the palmultang extract to the subject. The composition of the present invention remarkably reduces side effects, such as enlargement of the spleen, which are caused by the administration of G-CSF alone for proliferation and differentiation of the stern cells, through administration in combination with the palmultang extract, thereby further promoting the proliferation and differentiation of stem cells. | 04-14-2016 |
20160120836 | PHORBOL ESTER COMPOSITIONS AND METHODS OF USE FOR TREATING OR REDUCING THE DURATION OF CYTOPENIA - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester in combination with G-CSF or in combination with EPO, are provided for the treatment of cytopenia in mammalian subjects. The compositions and methods also reduce the duration of cytopenia such as neutropenia, thrombocytopenia, and/or anemia. | 05-05-2016 |
20160120874 | AGENTS FOR TREATING MULTIPLE MYELOMA - The present invention relates to the use of compounds of a cannabinoid nature for inhibiting viability with increasing doses of myeloma cell lines. Furthermore, said compounds have been shown not to affect CD34+ cells (normal hematopoietic progenitors) in terms of viability and proliferation. For this reason, the invention paves the way for the use of compounds of a cannabinoid nature as a promising therapy against multiple myeloma and related diseases. | 05-05-2016 |
20160120897 | DEXTRAN SULFATE FOR USE IN MOBILIZATION OF CELLS - Dextran sulfate in a range of 3500 and 9500 Da is employed to mobilize cells, such as stem and/or progenitor cells and certain white blood cells, in particular lymphocytes, into the peripheral blood of a subject. Dextran sulfate has a very fast cell mobilizing effect that implies that any cell harvest can be started almost immediately following dextran sulfate administration. | 05-05-2016 |
20160128966 | METHODS FOR TREATING LEUKOPENIA AND THROMBOCYTOPENIA - The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor. | 05-12-2016 |
20160129105 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention. | 05-12-2016 |
20160136265 | PHARMACEUTICAL COMPOSITION FOR VIRAL IMMUNOTHERAPY AND USES THEREOF - The present disclosure relates to a method of overcoming host immune tolerance in a subject having chronic hepatitis B virus (HBV) infection, comprising administering to the subject an immunomodulatory agent and a recombinant HBV vaccine, such that the immune tolerance of the chronic HBV infection in the subject is overcome. Moreover, the present disclosure relates to a method of treating chronic HBV infection in a subject in need thereof, comprising administering to the subject a first anti-viral agent, an immunomodulatory agent and a recombinant hepatitis B vaccine, such that the HBV infection in the subject is treated. | 05-19-2016 |
20160137695 | HORMONE SECRETION REGULATOR, COMPOSITION CONTAINING SAME, AND METHOD FOR CONTROLLING HORMONE SECRETION USING SAME - Provided are a hormone secretion modulator including a peptide derived from telomerase, more particularly, a peptide including an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having a sequence identity of at least 80% with SEQ ID NO: 1, or a fragment thereof, a pharmaceutical composition including the hormone secretion modulator, and a use of the pharmaceutical composition for treatment, alleviation, or prevention of diseases caused by excessive or deficient levels hormones. | 05-19-2016 |
20160143995 | Method of Treating Intracellular Infection - The present invention provides a method of treating an intracellular infection in a subject wherein the method comprising administering to the subject an IAP antagonist. In certain embodiments the IAP antagonist is a Smac mimetic. | 05-26-2016 |
20160151323 | METHODS FOR TREATING LEUKOPENIA AND THROMBOCYTOPENIA | 06-02-2016 |
20160151391 | NITRATED LIPIDS AND METHODS OF MAKING AND USING THEREOF | 06-02-2016 |
20160158186 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF TO TREAT RECURRENT MALIGNANT GLIOMA OR PROGRESSIVE SECONDARY BRAIN TUMOR - Methods and compositions suitable for the treatment of malignancies such as recurrent glioma and progressive secondary brain tumor are disclosed. These methods employ a hexitol derivative such as dianhydrogalactitol, a derivative or analog of dianhydrogalactitol, diacetyldianhydrogalactitol, or a derivative or analog of diacetyldianhydrogalactitol. The compositions can include such hexitol derivatives. | 06-09-2016 |
20160184417 | Methods and Compositions for Inhibiting Diseases of the Central Nervous System - Methods and compositions for treating central nervous system diseases and disorders are disclosed. | 06-30-2016 |
20160186210 | COMPOSITIONS AND METHODS FOR IDENTIFYING LATENTLY INFECTED CELLS - The present disclosure provides for recombinant nucleic acids, and cells and virions comprising the recombinant nucleic acids, that can be used to identify, isolate, and/or purify cells latently infected with immunodeficiency virus. A subject recombinant nucleic acid includes (a) a first nucleotide sequence encoding a first reporter polypeptide that produces a first detectable signal, where the first nucleotide sequence is operably linked to an immunodeficiency virus promoter and is translated as an early gene; and (b) a second nucleotide sequence encoding a second reporter polypeptide that produces a second detectable signal that is distinguishable from the first detectable signal, where the second nucleotide sequence is operably linked to a non-immunodeficiency virus promoter. In some aspects, the first and second nucleotide sequences are both positioned between a shared 5′ long terminal repeat (LTR) and a shared 3′ LTR. Also provided are related methods. | 06-30-2016 |
20160193294 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | 07-07-2016 |
20160193313 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA | 07-07-2016 |
20160250292 | In Vivo Individualized Systemic Immunotherapeutic Method and Device | 09-01-2016 |
20160250343 | COMBINATION THERAPY FOR TREATMENT OF CANCER | 09-01-2016 |
20160374983 | COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER - The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer. | 12-29-2016 |
20160375061 | COMPOSITION INVOLVED IN REGULATING ENERGY CYCLE, INFLAMMATION AND INSULIN RESISTANCE DYSFUNCTIONS, AND USE THEREOF PARTICULARLY IN CARDIOMETABOLIC DISEASES - A composition suitable for use as a health product, including a mixture of active ingredients made up of at least: a lactoserum hydrolysate with a molecular weight between 200 and 5000 daltons, alpha-lactalbumin, at least one AMPK, MAPK, PPAR and/or SIRT1 cycle regulator, and milk calcium. The composition is particularly useful as a medical nutrition product or orally administered drug, to prevent and/or combat various diseases. | 12-29-2016 |
20160375091 | Composition for Treating Prostate Cancer - The present invention relates to a composition for treating prostate cancer and, more specifically, to a composition for treating prostate cancer, which contains a peptide derived from telomerase and is effective in inhibiting growth and metastasis of prostate cancer cells. In addition, the present invention provides a composition and method for treating prostate cancer, wherein, when prostate cancer is treated, docetaxel and the peptide derived from telomerase are co-administered, thereby having a synergetic therapeutic effect compared with administration alone. Particularly, the present invention provides a treatment method useful for patients who do not have a sufficient anticancer effect merely through administration of docetaxel alone and patients who have hormone resistance. | 12-29-2016 |
20180021253 | PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY | 01-25-2018 |
20190142896 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RADIATION-RELATED DISORDERS | 05-16-2019 |
20190144517 | PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOSIS PROMOTION ANTIBODY, AND APPLICATION OF PROTEIN | 05-16-2019 |
20190145960 | COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF | 05-16-2019 |